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Abstract
Cyclin-dependent kinases (CDKs) are the master regulators of the eukaryotic cell cycle.
To become activated, CDKs require both regulatory phosphorylation and binding of
a cognate cyclin subunit. Using a series of DEER and NMR experiments, we studied
the activation process of the G1/S kinase Cdk2 in solution. We show that catalytically
inactive Cdk2 readily adopts multiple active-like states for efficient dephosphorylation,
and that regulatory phosphorylation on the activation loop enhances allosteric coupling
with the cyclin subunit. We then used DEER and FRET experiments to measure
the binding of multiple CDK inhibitors and developed a thermodynamic model that
describes the allosteric coupling between regulatory phosphorylation, cyclin binding
and inhibitor binding. We reveal that the allosteric coupling between these biochemical
effectors is responsible for the differential recognition of Cdk2 and Cdk4 inhibitors.
Finally, we used sequence analysis, DEER, FRET and activity assays to identify and
measure the effects of mutating an allosteric hub that has diverged between Cdk2 and
Cdk4. We demonstrate that this hub controls the strength of allosteric coupling, and
that the altered architecture and allosteric wiring of Cdk4 leads to compromised activity
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1.1 An introduction to the protein kinase fold
Protein kinases are an indispensable component of cellular function. Their role is simple:
catalyze the transfer of the γ-phosphate from ATP to a peptide substrate, a task that,
when performed correctly, forms the basis for much of the signalling transduction in
living cells1. Despite the relatively uncomplicated nature of what they do, the ubiquity
of protein kinases in cellular signalling and the disastrous consequences of uncontrolled
kinase expression and activity require a nuanced understanding of how different kinases
in the >500-member kinase family work.
At the time of this writing, it has been thirty years since the x-ray structure of
a protein kinase was first reported2. A seminal work, the structure (of cAMP pro-
tein kinase, commonly known as PKA) illustrated the basic fold of a kinase (Figure
1.1): one lobe containing five antiparallel β-sheets and an α-helix (the “αC-helix”), a
larger lobe composed mostly of α-helices, and, in between, an ATP-binding cleft and









Figure 1.1: The first reported x-ray structure of a protein kinase, PKA (PDB: 2CPK).
The structure depicts a bilobal fold with several key domains conserved across all protein
kinases.
Structures of other kinases soon followed, demonstrating that despite the significant
differences in the amino acid sequences of protein kinases, the kinase fold itself is highly
conserved. To date, roughly half of the human kinome has been characterized struc-
turally and deposited to the Protein Data Bank4, providing a framework for comparing
structures across the kinase family, identifying the structural basis for behaviors unique
to particular kinases and even designing inhibitors for kinases implicated in human
disease.
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These structures have also raised at least as many interesting questions as they have
answered. Protein kinases represent a constant and delicate thermodynamic balancing
act exquisitely dependent on protein structure. Consider the following:
• a kinase must be able to perform its function, but only when and where called upon
to do so by the cellular environment (a kinase must have control mechanisms).
• a kinase must be able to bind the same phosphodonor as the other kinases (Mg2+-
ATP), but it must be able to distinguish and bind its own phosphoacceptor sub-
strate (a kinase must have specificity).
• a kinase must be able to maintain its own structure, but be malleable enough so
as to undergo the structural transitions necessary for the previous two conditions
(a kinase must be dynamic).
These conditions have imposed a set of challenges that evolution has dealt with in both
dramatic and subtle ways. This work represents a small dent5 in the understanding of
how one particular kinase, Cdk2, works.
1.2 An introduction to cyclin dependent kinase 2
The cyclin-dependent kinases (CDKs) are a subfamily in the CMGC group of kinases.
Grouped together because of their dependence on a cyclin binding partner for activity,
the human CDKs comprise at least twenty members, four of which have been identified
as the central regulators of the cell cycle in all eukaryotes. Cdk1 orchestrates progression
through mitosis, Cdk2 controls the G1/S transition, and Cdk4 and Cdk6 trigger cell






Figure 1.2: CDKs 1,2,4 and 6 comprise the regulatory checkpoints for the eukaryotic
cell cycle. Adapted from [7].
The CDKs are inactive as monomeric kinases and require two separate steps for
activation. In the canonical model developed for Cdk2, the kinase is first phosphory-
lated on the A-loop on a specific site (T160 in Cdk2) by a Cdk activating kinase (CAK)
complex8, and is subsequently activated by binding of a cognate cyclin subunit9. While
CAK is active throughout the cell cycle, the expression of each cyclin subunit is re-
stricted to a specific cell cycle stage, ensuring coordinated progression through the cell
cycle.
Cdk2 has been extensively characterized by crystallography, allowing for the identi-
fication of its conformational endpoints. Monomeric Cdk2 adopts an autoinhibited con-
formation in which the αC-helix swings out of the active site, breaking a catalytically-
important salt bridge (“αC-out”), and the A-loop folds into the active site, blocking
substrate binding (“Aloop-in;” Figure 1.3, left)10. Cyclin binding triggers rotation of
the αC-helix into the active site (“αC-in”) and refolding of the A-loop into an extended
conformation that permits substrate binding (“Aloop-out;” Figure 1.3, right)11. Cy-
clin binding also buries the phosphorylated T160 residue, blocking dephosphorylation
and inactivation of the kinase12. This is thought to facilitate the abrupt switch-like
5
activation of Cdk2 at the G1/S boundary.
The numerous static x-ray structures of Cdk2 have provided key insights into the
allosteric effects of both cyclin binding and phosphorylation on Cdk2 activation, as
well as a wealth of information about the stable conformational states of the kinase.
The extent to which cyclin and phosphorylation act through allostery, and how Cdk2
transitions between these macrostable states, however, remains an open question, and

















Figure 1.3: X-ray structures of Cdk2 in the Aloop-in/αC-out and Aloop-out/αC-in
states (PDB: 1HCK and 1JST), accompanied by schematics of the respective A-loop
and αC-helix conformations. The segment of the A-loop highlighted in the schematics
refolds from a helix (αL12) in the Aloop-in state to an anchoring β-strand in the Aloop-
out state. Adapted from [13].
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1.3 The implication of Cdk2 in cancers
Pathogenesis at the level of individual unregulated proteins is often extremely difficult
due to the complex network of protein interactions required for cellular function. How-
ever, there have been some indisputable triumphs in identifying oncogenic drivers in the
kinase field, the most salient of which is the identification of BCR-ABL as the cause of
chronic myelogenous leukemia (CML). The road to treatment for this disease spanned
some forty years, from the initial description of the Philadelphia Chromosome14, to
the identification of the specific deregulated tyrosine kinase15 to the development of
imatinib, the first FDA-approved protein kinase inhibitor16, and many other significant
breakthroughs along the way17. At the time of this writing, there are 62 FDA-approved
small molecule kinase inhibitors for the treatment of cancer and inflammatory diseases18.
Although Cdk2 is not a classic oncogene, it has been implicated in several types of
cancer, most commonly through the overexpression of its binding partner cyclinE19,20
(Figure 1.4 a,b) and low molecular weight isoforms thereof21. More recently, high ex-
pression of Cdk2 itself has been shown to be a possible driver of glioblastoma22 (Figure
1.4c).
High-grade serous ovarian cancer
CyclinE 
(a) High grade serous ovar-
ian cancer; adapted from
[19].
Triple negative breast cancer
High CyclinE 
(b) Triple negative breast
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Figure 1.4: Survival curves showing that high expression of cyclinE or Cdk2 is correlated
with worse long term outcomes in cancer patients.
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Although a number of inhibitors have been developed for Cdk2, all of them have
failed out of clinical trials due to a lack of efficacy and/or off-target toxicity. Although
there are many theories as to why these inhibitors have not been met with the same
degree of success as with other kinases, a true mechanistic understanding of how the
inhibitors bind to and interact with the intrinsic allosteric regulation of the kinase itself
has not been contended with. This is the focus of chapter 3.
1.4 The role of the architecture of the CDK core in al-
losteric regulation
The CDKs share a high degree of sequence conservation across the subfamily, and sev-
eral members have been shown to compensate for one another in cells. However, there
are significant differences in both the expression profile of the cyclins, as well as sequen-
tial divergence in the residues that comprise the core of the kinase. For example, the
activation pathway of Cdk4/6 differs from that of the other cell cycle CDKs23. Expres-
sion of the cognate cyclin, cyclinD, is gradual rather than switch-like, and, unlike with
Cdk2:cyclinA which is effectively trapped in the phosphorylated state as a complex,
Cdk4:cyclinD complexes are continually phosphorylated and dephosphorylated on the
A-loop. Reversible A-loop phosphorylation allows the activity of Cdk4:cyclinD com-
plexes to be tuned by growth factors, which shift the balance towards phosphorylation
by enhancing CAK activity. Reversible phosphorylation is possible because Cdk4, un-
like other CDKs, does not switch to the active state when cyclinD binds24,25, leaving the
activation loop accessible to phosphatases23. Thus, the degree to which cyclin binding
is coupled to kinase activation has diverged between Cdk1/2 and Cdk4/6 in a manner
that reflects a biological requirement for altered activation dynamics. The role of key
sequential differences in the activation and inhibitor binding profiles between Cdks 1,2
8
and 4 comprise the focus of chapter 4.
Chapter 2
Allostery governs activation of
Cdk2
2.1 Background
The requirement of both a cyclin subunit and phosphorylation on T160 for activation of
Cdk2 is well-documented8,9,26. However, the extent to which each of these modulators
individually contributes to Cdk2 activation, why they are only able to activate Cdk2 in
concert, and whether Cdk2 is able to adopt an active-like conformation without them
is unclear. This gap in understanding arises from the following technical challenges:
• The x-ray structure of the unphosphorylated Cdk2 monomer depicts the kinase in
the canonical Cdk2/Src-like autoinhibited state, in which the αC-helix is rotated
out of the active site, and the activation loop has formed a β-hairpin and a short
helical turn (αL12 helix) for stability (Figure 1.3). Given the propensity for x-
ray crystallography to force its subject into a single conformational state, it is
impossible to judge how dynamic Cdk2 is in the absence of its modulators.
9
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• The x-ray structure of the unphosphorylated Cdk2:cyclin complex is that of a
symmetric dimer of dimers (P6222 space group; figure 2.1), a structure that forms
at the high protein concentration needed for crystallization. This likely forces the
kinase into an active-like conformation and therefore does not permit insight into










Figure 2.1: The x-ray structure of the unphosphorylated Cdk2:cyclinA complex (PDB:
1FIN), which forms a dimer of dimers. The presence of a second complex likely influences
the conformational state of the first, thus confounding attempts to ascertain the effect
of cyclin alone.
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• In kinase activity assays, neither the unphosphorylated Cdk2:cyclin complex, nor
the phosphorylated Cdk2 monomer has appreciable kinase activity, thus making
it difficult to directly measure the individual contributions of cyclin binding and



























Figure 2.2: Neither the phosphorylated Cdk2 monomer (black), nor the unphosphory-
lated Cdk2:cyclin complex (yellow) have sufficient kinase activity to differentiate the
effects of cyclin binding and phosphorylation.
12
Operating under the assumption that the key determinant for activity is not the
conformational state of any single Cdk2 molecule, but rather the conformation of the
ensemble of protein molecules, we chose to circumvent these challenges by using biophys-
ical spectroscopy tools (fluorescence and EPR) to track important structural domains
of Cdk2 while subjecting the samples to physiologically-relevant biochemical conditions.
2.1.1 Cyclin and phosphorylation synergistically affect the Cdk2 acti-
vation loop
We probed the local environment of the Cdk2 activation loop in four biochemical states:
unphosphorylated monomer (“Cdk2”), phosphorylated monomer (“pCdk2”), unphos-
phorylated complex (“Cdk2:cyclinA”) and phosphorylated complex (“pCdk2:cyclinA”).
We chose this experiment because of its relative simplicity: conjugate an environmentally-
sensitive fluorophore to an engineered cysteine on the A-loop of the kinase, excite the
fluorophore and measure the emission spectra.
We labeled a “cys-lite1” mutant of Cdk2 (with the endogenous, solvent-exposed C177
mutated to a serine) with the solvatochromic fluorophore acrylodan on two residues on
either side of the T160 phosphorylation site: R157C and E162C. Acrylodan, which
conjugates to the cysteines by a thioether bond, is highly sensitive to the polarity of its
surrounding environment. These changes are reflected in the energy of the excited state,
which manifests as a change in the fluorophore’s emission wavelength (Stokes shift)27.
In the context of this experiment, an increase in the emission wavelength (redshift) can
generally be associated with greater exposure to the solvent or polar residues, and a


























fluorophore on R157C fluorophore on E162C
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18 nm12 nm
Figure 2.3: Emission spectra of acrylodan conjugated to two different sites on the A-
loop of Cdk2 (R157C, left; E162C; right). The fluorophore was excited at 370 nm. Only
the pCdk2:cyclinA samples (blue) exhibited large Stokes shifts, suggesting that cyclin
and phosphorylation together affect the A-loop differently than either alone.
In both sets of spectra, the emission profile of the pCdk2:cyclinA sample was markedly
different from that of the others; the R157C sample exhibited a redshift of approx. 12
nm, while the E162C spectrum blueshifted by 18 nm (Figure 2.3). While it is difficult
to deduce the structure of a protein domain based on the emission profile of a con-
jugated dye (due to the complex set of electronic effects that contribute to a Stokes
shift), the qualitative differences pointed to a profound result that is not immediately
obvious in the x-ray structures of Cdk2: cyclin-binding and phosphorylation on T160
together affect the local environment of the tip of the A-loop in a way that neither can
achieve alone. This result led us to study the conformational balance of Cdk2 in a more
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quantitative fashion.
2.1.2 How to determine how much of the kinase is in a particular
conformational state
Due to the ensemble nature of protein kinases in cells, it is often enough to measure
the steady state average of kinase activity or structure to reap useful information about
the biochemical state. However, in order to develop a quantitative model that ties the
biochemical state to kinase conformation, it is necessary to be able to break down the
ensemble into its constituent subpopulations. We thus chose double electron-electron
resonance (DEER) spectroscopy to track conformational changes of Cdk2 in solution.
DEER, which was used to obtain the bulk of the results in this chapter, is one of sev-
eral types of experiments that comprise electron paramagnetic resonance spectroscopy
(EPR), and is an underused technique in structural biology. The fundamental concepts
required to understand the method are summarized below.
The Zeeman effect
(EPR) spectroscopy is a method used to study the properties of materials with unpaired
electrons. EPR exploits a phenomenon called the Zeeman effect, which describes the
energy gap between the ground and excited states that unpaired electrons can occupy in
the presence of a magnetic field B0 because they possess an intrinsic angular momentum
(called spin). An unpaired electron in the ground state can be promoted to the higher
energy state by absorbing a photon of energy equal to the gap between the two states
(Figure 2.4):
hv = geµBB0 (2.1)
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where ge is the g-factor for an electron, µB is the Bohr magneton and B0 is the strength of
the magnetic field. A simple example of an EPR experiment is one in which the number
of unpaired electrons in a sample are counted; this is typically done by exposing the
sample to a fixed microwave radiation source and a magnetic field of variable strength,
and integrating the absorption spectrum that results.
Figure 2.4: A basic illustration of the Zeeman effect.
Double electron-electron resonance
DEER spectroscopy combines the basic concept of EPR with the phenomenon of mag-
netic dipolar coupling, a through-space interaction that occurs when two (for our pur-
poses, but in principle this is true in a pairwise fashion for any n >1) unpaired electrons








(3 cos2 θab − 1) (2.2)
where rab represents the distance between the two electrons (notice that ωab drops off
in a manner inversely proportional to the third power of the distance), µB is the Bohr
magneton, gi is the g factor for each electron, and θab is the angle between the dipolar
axis and the magnetic field.
DEER in protein structural biology makes use of the Zeeman effect, dipolar coupling
and some amount of mathematical wizardry to back out the distances between two parts
of a protein, and thereby ascertain its conformational states. In practice, this involves
the following:
1. Preparation of a purified protein sample with two spin labels (each of which con-
tains one unpaired electron) conjugated to each protein molecule. There are sev-
eral stable nitroxide spin labels available for this purpose, the most commonly used
being MTSSL (Figure 2.5). The use of MTSSL requires formation of a disulfide
bond to engineered cysteine residues on the protein. This requires the removal of
labile, endogenous cysteine residues (a more challenging alternative is to introduce
the unnatural amino acid p-acetyl-L-phenylalanine and label with a hydroxylamine
spin label28). For higher quality data, the buffer should be deuterated and the








Figure 2.5: The chemical structure of (1-oxyl-2,2,5,5-tetramethylpyrroline-3-
methyl)methanethiosulfonate (MTSSL), the nitroxide spin probe used to label Cdk2
in the DEER experiments.
2. Application of the DEER technique to the sample, in which the frozen sample
is placed inside a resonant cavity and exposed to a fixed magnetic field as well
as a specific pulse sequence of microwave radiation (Figure 2.6). The different
microwave pulses provide the energy needed to excite one population of spins
(arising from the Zeeman effect) and measure their effect (due to dipolar coupling)
on nearby spins (i.e. measure what happens to one unpaired electron on the
protein when the other unpaired electron on the protein is excited). The recorded
measurement is the amplitude of the spin echo of the second population of spins,
















Figure 2.6: The four pulse DEER experiment. Adapted from [29].
3. Fitting of the DEER data to interspin distance distributions, which is an ill-posed
problem (i.e. there is no unique solution to a particular set of primary data in
DEER). This requires the user to iteratively generate distributions for known
distances and convolve each distribution with the kernel function (Eq. 2.3) to










where Ci is the proportionality constant
µ2Bgagb
~ from Eq. 2.2, t is time, and θ is
the angle between the dipolar axis and the magnetic field. The final step in DEER
analysis is to fit the generated, convolved distribution to the primary data.
The practical Cdk2 DEER experiment
Given the uneven geometry of the kinase fold, the locations of catalytic residues that
must not be perturbed, and the propensity for some domains of the kinase to be more
dynamic than others, some care was required in the spin labeling of Cdk2. We chose to
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track the movements of the activation loop and αC-helix not only due to their impor-
tance in Cdk2 activity, but also because they appear to move the most across different
x-ray structures, therefore maximizing our chance of capturing the active-inactive con-
formational transition in Cdk2.
On the activation loop of Cdk2, the residues between 154 and 161 move the farthest
distance, determined from measuring the Cα-Cα distances for each residue across the
Cdk2 and pCdk2:cyclinA x-ray structures. We immediately ruled out P155 and T160
because of their special properties: P155 due to the special role of prolines in pro-
tein conformation30 and T160 phosphorylation in Cdk2 activity. We also excluded the
residues immediately preceding and succeeding P155 and T160 due to their proximity
to the important residues. We ultimately chose R157C (Figure 2.7) as the labeling site
for MTSSL: it was located in an appropriate region of the activation loop, it replaces a
relatively bulky (albeit polar) residue with a bulky spin label and it had already been
validated as a construct that responds to cyclin and phosphorylation in the acrylodan
experiments. Further validation demonstrated that the Cdk2 R157C construct labeled










Figure 2.7: Crystallographic temperature factors (left) and spin label conformational






























































































Figure 2.8: a) Mass spectra of unphosphorylated Cdk2 (DEER A-loop construct) with-
out (black) and with (red) two MTSSL spin probes (+368 Da). The mass spectrum
of phosphorylated Cdk2 with two MTSSL probes is shown in blue. b) Size exclusion
chromatography traces for unphosphorylated, spin-labeled monomeric Cdk2 (DEER A-
loop construct; green) and Cdk2:cyclinA dimer (yellow) as well as free cyclinA (blue),
demonstrating that the spin-labeled kinase binds the cyclinA subunit. The SDS-PAGE
gel shows fractions from the Cdk2:cyclinA dimer run confirming formation of the 1:1
complex and demonstrating that the sample was prepared with excess cyclinA. Pro-
tein samples used for reference Cdk2 and cyclinA markers (lanes 1 and 2) had been
previously validated. This analysis was performed on the sample used for the DEER
experiment. c) Kinase activity assays showing catalytic activation of pCdk2 WT, the
unlabeled DEER A-loop construct (pCdk2-Cyslite2-R157CA93C), and the DEER A-
loop construct labeled with 2 MTSSL spin labels. We confirmed that the spin labels
remained on the kinase in the kinase activity assay buffer by mass spectrometry.
For the αC-helix, our choice for labeling site was essentially limited to S46C, which
is located at the tip of the helix, unlikely to rotate into the active site of the kinase, and
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distant from the critical residues R50 and E51. Cdk2 S46C was also validated by mass
spectroscopy and activity assays; the presence of the spin label did not significantly
affect the ability of cyclinA to bind and activate spin-labeled pCdk2 (Figure 2.9).
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Figure 2.9: a) Mass spectrum of the phosphorylated Cdk2 αC-helix construct with two
MTSSL labels on S46C and A93C. Expected mass: 34,573 Da. b) Kinase activity assays
showing catalytic activity of the αC-helix probe construct compared to WT Cdk2. The
activity of the +2xMTSSL sample was measured with protein previously used in the
DEER experiment itself.
As for the choice of reference spin label, we chose A93C on the αD-helix, which
remains immobile across the different x-ray structures of Cdk2. The aforementioned
validation experiments were performed with the A93C construct.
Having chosen labeling sites, we proceeded with the DEER experiments to ascertain
the conformational states of Cdk2 in solution.
2.2 Results
One pair of spin labeling sites (A93C, R157C) was used to track the A-loop between the
Aloop-in and the Aloop-out states. A second pair of labeling sites (A93C, S46C) was
used to track the αC-helix between αC-out and αC-in states. Assignment of peaks in
the spin-spin distance distributions31 to these structural states was achieved by reference
22


































Figure 2.10: MTSSL rotamers visualized on the x-ray structures of Cdk2 using the
PyMOL plugin MtsslWizard. Calculated ensemble distance distributions were used
to assign conformational states to Gaussian populations from the DEER experiments
measuring a) the A-loop of Cdk2 and Cdk2:cyclinA, showing that Cdk2 samples the
Aloop-out1 state, and that Cdk2:cyclinA adopts the Aloop-out2 state b) the αC-helix
of Cdk2 and Cdk2:cyclinA, showing that the MTSSL probe is more constrained in the
presence of cyclin, leading to different Gaussian centers for the αC-in conformation
In experiments tracking the A-loop, monomeric unphosphorylated Cdk2 (“Cdk2”)
exhibited one predominant short-distance peak assigned to the Aloop-in state, and a
minor longer-distance peak corresponding to an Aloop-out state (Figure 2.11). This
demonstrates that monomeric Cdk2 samples the Aloop-out state to a substantial de-
gree (13 ± 6%), as suggested by a recent molecular dynamics study33. Addition of
cyclinA (“Cdk2:cyclinA”) resulted in the Aloop-out peak becoming dominant, but a
subpopulation sampling the Aloop-in state was still present, indicating an incomplete
shift to the Aloop-out state (Figure 2.11).
23











































































Figure 2.11: DEER experiments tracking the A-loop (left) and αC-helix (right).
Tikhonov-derived distance distributions are shown for monomeric Cdk2 and
Cdk2–cyclinA dimer in the unphosphorylated state. Dashed black lines represent Gaus-
sian fits to the DEER data. Peak assignments are based on spin–spin distance calcula-
tions (Figure 2.10). The spin labeling schemes are represented schematically. Data for
the αC-in inhibitor K03861 are shown in dark gray. P(r) is the probability of distance
r.
DEER data collected on T160-phosphorylated monomeric Cdk2 (“pCdk2”) were
similar to the unphosphorylated case, although the Aloop-in peak was shifted and broad-
ened (Figure 2.13), consistent with local disorder around the labeling site observed in the
x-ray structure of phosphorylated Cdk234. However, addition of cyclinA to this sample
(“pCdk2:cyclinA”) led to nearly homogeneous adoption of the Aloop-out state (Figure


































Figure 2.12: MTSSL rotamers visualized on the x-ray structures of Cdk2 using the
PyMOL plugin MtsslWizard. Calculated ensemble distance distributions were used
to assign conformational states to Gaussian populations from the DEER experiments
measuring a) the A-loop of pCdk2 and pCdk2:cyclinA, showing that pCdk2 has a similar
Aloop-out subpopulation to Cdk2 and that pCdk2:cyclinA adopts the Aloop-out3 state
b) the αC-helix of pCdk2 and pCdk2:cyclinA, showing that pCdk2:cyclinA is mostly







































































Figure 2.13: DEER experiments tracking the A-loop (left) and αC-helix (right).
Tikhonov-derived distance distributions are shown for monomeric Cdk2 and
Cdk2–cyclinA dimer in the phosphorylated state. Dashed black lines represent Gaussian
fits to the DEER data. Peak assignments are based on spin–spin distance calculations
(Figure 2.12). The spin labeling schemes are represented schematically. P(r) is the
probability of distance r. Data for phosphorylated Cdk2 monomer are plotted on a
different y axis scale for clarity.
The experiments tracking the αC-helix revealed conformational shifts that were
correlated to those of the A-loop, with a subpopulation of monomeric Cdk2 sampling
the αC-in state, and a larger cyclin-driven shift to the αC-in state when the kinase is
phosphorylated (Figure 2.11, 2.13). The inhibitor K03861, which has an αC-in binding

















Figure 2.14: The structure of the DFG-out Cdk2 inhibitor, K0386135.
These results are consistent with an allosteric conformational shift model36 (Figure
2.15), in which the kinase transitions in a concerted manner between Aloop-in/αC-out
and Aloop-out/αC-in states. The cyclin-driven population shift is described by the
allosteric coupling parameter α. The value of α can be estimated from the DEER data
to be 9 for unphosphorylated Cdk2, and 36 for phosphorylated Cdk2, indicating that
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Figure 2.15: Allosteric two-state model for cyclin binding to Cdk2, with K and K∗
representing the Aloop-in and Aloop-out states of the kinase, C representing the cyclin





senting microscopic equilibrium constants for cyclin binding to Aloop-out and Aloop-in
states, respectively. The coupling parameter α represents the fold change in Keq on cy-
clin binding. The bar graph summarizes the values of Keq and α derived from Gaussian
fits of the DEER data. Error bars represent 75% CIs, calculated from 50,000 simulations
of Gaussian fits to the primary data.
2.2.1 Cdk2 samples catalytically inactive Aloop-out states
We used paramagnetic relaxation enhancement (PRE) NMR experiments37 to further
probe the A-loop movements i. The A-loop of Cdk2 is invisible in NMR spectra due to
exchange broadening. Nonetheless, by incorporating a spin label on the same A-loop
site used for DEER, the position of the A-loop can be inferred through the effects of
the paramagnetic label on the spin relaxation of nearby elements of the kinase. In
monomeric Cdk2 the observed PRE effects were localized to the αG helix, the β3-αC
loop, the CMGC insert region and the αEF and αF helices, and were not affected by
phosphorylation (Figures 2.16 & 2.17). PRE calculations (see Methods) revealed that




































Figure 2.16: NMR PRE data for monomeric unphosphorylated Cdk2 (left), the unphos-
phorylated Cdk2:cyclinA dimer (middle) and the phosphorylated Cdk2:cyclinA dimer
(right) are mapped onto the respective X-ray structures. Ovals represent assignments
of PRE effects to specific structural states based on PRE calculations and black spheres
represent the R157C spin labeling site.
the effects on the αG helix and part of the β3-αC loop were consistent with the Aloop-
in state, but the other effects were not. Calculations performed on three Aloop-out
x-ray structures of Cdk2, differing in the position of the labeled segment of the A-loop,
indicated that these latter PRE effects were most consistent with the conformation
observed in the structure of Cdk2 bound to KAP (kinase associated phosphatase)38.
This structure is a rare example of a CDK adopting an Aloop-out state in the absence
of a cyclin subunit. Rather than being induced by KAP binding, it appears that Cdk2




































































































































































































Aloop-out2 calculated PRE (PDB ID: 1FIN)









































































αG helix CMGC insert αH helix αI helixαD helix αE helix










































































Aloop-out3 calculated PRE (PDB ID: 1JST)
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Figure 2.17: a) Plots of the PRE Ip/Id values for monomeric Cdk2, as well as calculated
Ip/Id for the Aloop-in state (black, based on the apo 1HCK x-ray structure) and the
Aloop-out1 state (gray, based on the KAP-bound 1FQ1 structure). The experimental
and calculated PRE effects are shown mapped onto the x-ray structure on the right.
PRE effects on the C-terminal half of the β3-αC loop, CMGC insert, αEF-helix and
αF-helix demonstrate that monomeric Cdk2 samples the Aloop-out1 state. Error bars
represent the standard error calculated from the signal-to-noise ratio of the entire spec-
trum. b) The PRE effects for phosphorylated monomeric Cdk2 are mapped onto the
x-ray structure. c) Experimental and calculated PRE Ip/Id values for Cdk2:cyclinA.
The PRE effect on the CMGC insert is consistent with adoption of the Aloop-out2 state
observed in the 1FIN x-ray structure. The PRE signature on the αG helix is consistent
with an Aloop-in subpopulation. Error bars represent the standard error calculated
from the signal-to-noise ratio of the entire spectrum. d) Experimental and calculated
PRE Ip/Id.
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For the Cdk2:cyclinA dimer, the PRE effects were more muted (Figure 2.16). In
the unphosphorylated dimer, they were localized predominantly to the CMGC insert
region, as predicted by PRE calculations, although there was a remnant of the αG helix
PRE effect seen in monomeric Cdk2 (Figure 2.17), consistent with the dimer sampling
the Aloop-in state as indicated by the DEER experiments. In the phosphorylated
Cdk2:cyclinA dimer, both the residual αG PRE effect and the CMGC insert PRE
effect largely disappeared, and calculations confirmed this to be consistent with the
homogeneous adoption of the Aloop-out conformation seen in the x-ray structure of the
phosphorylated dimer12.
Together with the DEER results, the PRE experiments help clarify that Cdk2 can
sample multiple Aloop-out states. These Aloop-out states all share the characteristic
β-sheet formed in the N-terminal segment of the A-loop (anchor 1), but they differ in
the positioning of the C-terminal segment of the A-loop (Figure 2.18). In the Aloop-out
state adopted by monomeric Cdk2 (termed “Aloop-out1”), this segment of the A-loop
is anchored onto the C-terminal lobe of the kinase through a second β-sheet interaction
(anchor 2). This feature is common in activated kinases39, but in Cdk2 the β-sheet is out
of register, and instead stabilizes an inactive conformation in which the T160 residue is
presented for dephosphorylation. In the unphosphorylated Cdk2:cyclinA dimer, anchor
2 is also formed, but its register is shifted by two amino acids, allowing more extensive
interactions with the cyclin subunit, while simultaneously blocking the substrate bind-
ing site (“Aloop-out2”). Finally, in the phosphorylated Cdk2:cyclinA dimer, anchor 2 is
broken, and the A-loop is further shifted toward the cyclin subunit and locked in place
by ionic interactions of the pT160 residue with three arginine residues (“Aloop-out3”).
Only in this Aloop-out3 state is the peptide substrate binding site formed. Kinase
activity assays confirmed that this is the only state that demonstrates appreciable ki-
nase activity 2.2. Comparison of the long-distance subpopulations measured by DEER
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revealed that these experiments also distinguish between the three Aloop-out states
(Figure 2.19). This provides a simple explanation for why monomeric Cdk2 remains
catalytically inactive when phosphorylated on T160, as the Aloop-out1 conformation
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Figure 2.18: Schematics representing the three Aloop-out states detected in the PRE
experiments. The spin labeling site on the A-loop is shown as a circle.
rAloop-out















Figure 2.19: The Aloop-out Gaussian fits to the DEER experiments shown in Figures
2.11 & 2.13, highlighting the detection of the three different Aloop-out states.
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2.3 Methods
Expression and purification of Cdk2 and cyclinA
Human Cdk2 (residues 1-298 with a TEV-cleavable N-terminal hexahistidine tag in
pCDFduet) and mutants were expressed in BL21(DE3) Escherichia coli overnight at
18 °C. Coexpression with yeast CAK was used to prepare T160-phosphorylated Cdk2,
and mass spectrometry confirmed homogeneous single phosphorylation in these samples
(see Figures 2.8 and 2.9). Harvested cell pellets were lysed using an Emulsiflex C3
homogenizer (Avestin). Lysates were clarified by centrifugation and loaded onto HisTrap
HP IMAC columns (GE), washed with lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl,
10% glycerol) and eluted with elution buffer (1x PBS, 500 mM imidazole, 10% glycerol).
Imidazole was immediately removed by desalting using a HiPrep 26/10 column (GE),
and the hexahistidine tag was cleaved overnight with TEV protease (1:10 TEV:6HisCdk2
w/w). Protein was further purified using a Superdex 75 10/300 GL size exclusion column
(GE).
Bovine CyclinA3 (residues 171-432 with a non-cleavable C-terminal hexahistidine
tag) was expressed overnight in BL21(DE3)pLysS Escherichia coli. Cell pellets were
lysed as above, lysates clarified, loaded onto HisTrap HP columns, and eluted using a 0-
500 mM linear imidazole gradient (50 mM Tris pH 8.25, 300 mM NaCl, 10% glycerol).
CyclinA was stabilized with the immediate addition of 100 mM MgCl2 and further
purified using a HiLoad 16/600 Superdex 200 size exclusion column (50 mM Tris pH
8.25, 100 mM MgCl2, 5 mM 2-mercaptoethanol).
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DEER spectroscopy
DEER samples were prepared by labeling “Cys-lite2” constructs of Cdk2 (C118A,
C177S, A93C, and either R157C or S46C for A-loop and αC-helix experiments, re-
spectively) with a 2.25-fold excess of MTSSL spin label, at a protein concentration of
50-100 µM. Labeled kinase was purified by size exclusion chromatography and concen-
trated to 60-80 µM, buffered in 1x PBS pH 7.4, 10 mM MgCl2 and 10% d8-glycerol in
D2O and rapidly frozen in 1.1 mm ID/1.6 mm OD glass capillary tubes. For samples
containing inhibitors, deuterated DMSO was used and inhibitor concentrations were 250
µM. DEER spectra were acquired at 65 K using the standard deadtime-free four-pulse
sequence (π/2 = 16 ns and π = 32 ns)40 on an Elexsys E580 spectrometer (Bruker)
equipped with an EN5107 resonator operating at Q-band frequencies (∼34 GHz). The
pump frequency was set to the maximum of a two-pulse echo detected field sweep and
the observe frequency was set to 24 G up-field. DEER waveforms were analyzed using
Venison, a custom program written in Python based on DeerAnalysis 2017. Briefly, dis-
tance distributions were fit to the background-corrected waveforms using unconstrained
Tikhonov regularization, with smoothing parameter λ chosen using the L-curve and
leave-one-out cross validation (LOOCV). Features of the spectrum that were tightly
coupled to the background model and contributed to unstable populations that were
both distinct from the primary distance populations and beyond the limit of sensitivity
of the 6 µs evolution time (∼58 Å) were suppressed by incorporating them into the
background model. Tikhonov regularization was repeated on the corrected waveform.
The Tikhonov distribution was used to initialize fitting of the waveforms to a sum of
Gaussians model in order to determine the population centers of the spin-spin distances,
as well as the widths and mole fractions. The appropriate number of Gaussian subpop-
ulations was determined by selecting the fewest number of Gaussian centers that met
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the RMSD minimization threshold calculated by the Bayesian information criterion41.
Confidence intervals for Gaussian fits were calculated with Monte Carlo simulations of
Gaussian fits to the background-corrected waveforms. All uncertainties quoted in main
text and figures represent 75% confidence intervals.
Predicted spin-spin distance distributions were calculated from x-ray structures us-
ing the PyMOL plugin mtsslWizard32 with the thorough conformational search setting
for generating MTSSL spin probe ensembles. Calculated distance distributions agreed
well with experiment, allowing unambiguous assignment of peaks in the experimental
distance distributions to individual structural states (Figures 2.10 and 2.12). In par-
ticular, these calculations confirmed that the Aloop-out1, Aloop-out2, and Aloop-out3
states should give rise to increasingly longer spin-spin distances in A-loop DEER ex-
periments, and that the 41 Å peak observed in the αC-helix DEER experiments with





Having determined the intrinsic conformational balance of Cdk2 and how it is modu-
lated by cyclin and phosphorylation, we next turned our focus to how small-molecule
inhibitors interact with the dynamic kinase. Across the spectrum of inhibitors devel-
oped specifically to target the Cdks, there has been a significant number of preclinical
and clinical studies to determine their potency, efficacy and toxicity profiles both in
vitro and in vivo. As is true of the majority of drug discovery efforts, most of these drug
candidates have failed in clinical trials (with the exception of the Cdk4/6 inhibitors
palbociclib, ribociclib and abemaciclib). Despite having glimpses into the biochemical
preferences of Cdk2 inhibitors through crystallography and ITC studies42, there has
not been a quantitative evaluation of how phosphorylation and/or cyclin-binding affect
Cdk2:inhibitor affinities, how the presence of inhibitors affect the Cdk2:cyclin affinity
and the extent to which the inhibitors drive conformational shifts in Cdk2.
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We thus sought to develop a quantitative model accounting for the Aloop-in/out
equilibrium, cyclin affinity and inhibitor affinity in both phosphorylated and unphos-
phorylated Cdk2. We used DEER and Förster resonance energy transfer (FRET) ex-
periments to measure Cdk2 conformation and centered our study around the following
seven inhibitors because they represent a variety of chemical scaffolds, intended targets
and clinical outcomes:
1. Flavopiridol (alvocidib; Figure 3.1) was the first Cdk inhibitor tested in clini-
cal trials43. The compound was derived from rohitukine, a natural product first
described in the late 1970s44, synthesized in the late 1980s45 and investigated
for its potential anti-inflammatory effects. Flavopiridol, which subsitutes a 2-
chlorophenyl group for a methyl in rohitukine, was soon discovered to inhibit
the Cdks46,47 and determined to have antitumor properties48. Flavopiridol is a
multi-Cdk inhibitor that has been crystallized bound to the Cdk2:cyclinA com-
plex in the active-like state, and has been shown to have a higher affinity for the
pCdk2:cyclinA complex than the monomer42. The compound has been tested in
numerous clinical trials against leukemias, lymphomas and various solid tumors,
but the inhibitor has not been approved mostly due to a lack of efficacy and
dose-limiting toxicities43. Flavopiridol was found to be partially effective against
chronic lymphocytic leukemia (CLL), but was also linked to tumor lysis syndrome
in a significant number of patients49. For the purposes of this study, we have









Figure 3.1: The chemical structure of the multi-Cdk inhibitor flavopiridol.
2. Roscovitine (seliciclib; Figure 3.2) was derived from the weak Cdk inhibitor
olomoucine, itself a derivative of adenine50. Roscovitine is a sub-µM inhibitor of
Cdks 1,2,5,7 and 951, and has been crystallized with both monomeric Cdk2 in the
Cdk2/Src-like inactive state52 and in the pCdk2:cyclinA complex in an active-like
state53. The compound has been tested in small scale clinical trials for Cushing
disease and non-small cell lung cancer, but these studies were terminated due to
unacceptable toxicities54 or unspecified reasons. For the purposes of this study,









Figure 3.2: The chemical structure of the multi-Cdk inhibitor roscovitine.
3. Dinaciclib (Figure 3.3) was developed through the optimization of pyrazolo[1,5-
a]pyrimidine-based structures using in vivo screening against an ovarian carcinoma
xenograft model55. Dinaciclib is a low nM inhibitor of Cdks 1,2,5 and 956. Di-
naciclib has failed in clinical trials for advanced breast cancer57, non-small-cell
lung cancer (NSCLC)58 and CLL59, among others, due to dose-limiting toxicities
including tumor lysis syndrome60. The compound has been crystallized with both
monomeric Cdk2 in the Cdk2/Src-like inactive state61 as well as the Cdk2:cyclinE
complex in the active-like state62, and has been shown to have a higher affinity for
the pCdk2:cyclinA complex than the monomer42. For the purposes of this study,










Figure 3.3: The chemical structure of the Cdk1/2/5/9 inhibitor dinaciclib.
4. AZD5438 (Figure 3.4) was developed through a series of substitutions on imida-
zole compounds63. AZD5438 inhibits Cdks 1,2 and 9 at low nM concentrations64.
The compound has undergone one clinical trial for the treatment of advanced
tumors, but the trial was terminated due to tolerability issues65. AZD5438 has
been crystallized with both monomeric Cdk2 in the Cdk2/Src-like inactive state
(with evidence of a second inhibitor-driven conformation of the A-loop!) as well
as with the Cdk2:cyclinA complex in the active-like state42, and has been shown
to have a higher affinity for the pCdk2:cyclinA complex than the monomer42. For










Figure 3.4: The chemical structure of the Cdk1/2/9 inhibitor AZD5438.
5. Palbociclib (Figure 3.5) is an FDA-approved66 Cdk4/6 inhibitor therapy for
HR+/HER2- breast cancer. The compound was developed through a series of
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optimizations, specifically designed to maximize the selectivity for Cdk4:cyclinD
over Cdk2:cyclinA, on a pyrido[2,3-d]pyrimidin-7-one core67,68. The resulting com-
pound, palabociclib, exhibited a remarkable 450-fold difference in IC50 values
between the Cdk4 and Cdk2 complexes, which is attributed to the differential
interactions of the modified substituents with the kinase active sites. Palbociclib
has been crystallized with both monomeric Cdk662 as well as a complex of Cdk6
and a cyclin from a herpesvirus69. Palbociclib is currently undergoing a large
number of clinical trials for other types of cancer. For the purposes of this study,








Figure 3.5: The chemical structure of the Cdk4/6 inhibitor palbociclib.
6. Ribociclib (Figure 3.6) is an FDA-approved70 Cdk4/6 inhibitor therapy for
HR+/HER2- breast cancer. Based on a pyrrolo[2,3-d]pyrimidine core (as opposed
to the pyrido[2,3-d]pyrimidine core of palbociclib), the structure and activity of
ribociclib are otherwise similar to those of palbociclib71. Ribociclib has been
crystallized with monomeric Cdk662. Ribociclib is currently undergoing a large
number of clinical trials for other types of cancer. There are several known mech-
anisms for resistance to Cdk4/6 inhibitors such as ribociclib (and palbociclib),
including an overexpression of cyclinE72 as well as the formation of noncanonical
Cdk2:cyclinD complexes73 that override the inhibition of the primary targets. For
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Figure 3.6: The chemical structure of the Cdk4/6 inhibitor ribociclib.
7. Abemaciclib (Figure 3.7) is a Cdk4/6 inhibitor therapy for HR+/HER2- breast
cancer74. The compound was developed through the optimization of a 2-anilino-
2,4-pyrimidine-[5-benzimidazole] scaffold that was discovered in a chemical screen75.
Although it was approved for the same disease and mechanism of action as palbo-
ciclib and ribociclib, the inhibitor has a different selectivity profile for the CDKs,
resulting in distinct therapeutic and toxicity outcomes71. Abemaciclib has been
crystallized with the Cdk6 monomer62. For the purposes of this study, we have











Figure 3.7: The chemical structure of the Cdk4/6 inhibitor abemaciclib.
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3.1.1 A note on the Cdk2 FRET experiment
The steady-state FRET experiment used in this study is a relatively simple one that
has been previously been described in detail76. The readout from the experiment is the
ratio between the intensity of the donor and acceptor fluorophores, providing a relative
measure of the distance between the two fluorophores (whereas the EPR experiments
serve as the accurate “molecular ruler”). Importantly, this obviates the need for a set
of donor-only samples that would otherwise be required in a typical FRET experiment.
The benefits of this experiment are thus:
• it requires extremely small amounts of protein and inhibitor due to the high quan-
tum yield of the attached fluorophores
• it can be infinitely scaled up
• it can generate many inhibitor titrations quickly in a high-throughput fashion
3.2 Results
3.2.1 Cdk2 inhibitors drive conformational shifts upon binding
We used DEER to probe the conformational effects of four ATP-competitive Cdk2
inhibitors: flavopiridol, roscovitine, AZD5438, and dinaciclib. All of the inhibitors
increased the Aloop-out1 subpopulation when bound to monomeric Cdk2, and also
promoted the Aloop-out2 subpopulation when bound to the Cdk2:cyclinA dimer (Figure





































Figure 3.8: DEER experiments tracking the A-loop (left) and αC-helix (right) in the
Cdk2 monomer, and Cdk2:flavopiridol complex. For the A-loop experiments, data are
also shown for Cdk2 bound to ADP (bottom). Solid lines represent Tikhonov-derived
distance distributions, while dashed black lines represent the Gaussian fits to the DEER
data. Peak assignments are based on spin–spin distance calculations. The spin labeling
schemes are represented schematically at the top.
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Figure 3.9: DEER experiments tracking the A-loop (left) and αC-helix (right) in the
Cdk2:dinaciclib, and Cdk2:roscovitine complexes.
Corresponding population shifts toward the αC-in state were also observed (Fig-
ure 3.8 & 3.9 right, 3.11), demonstrating that the Cdk2 inhibitors promote concerted
conformational shifts from the Aloop-in/αC-out state to the Aloop-out/αC-in state.
These shifts can be described by an allosteric coupling parameter β, analogous to the
parameter α for cyclin (Figure 3.12).
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Figure 3.10: DEER spectra (bottom) and spin-spin distance distributions (top) for Cdk2
bound to four Cdk2 inhibitors. Distance distributions were acquired by fitting DEER
spectra using Tikhonov regularization, and independently fitting to two Gaussian func-
tions representing Aloop-in and Aloop-out1 states. The calculated Aloop-out1 distance
distribution from the Cdk2:KAP structure (1FQ1) is shown in grey and scaled along the
y-axis for clarity. DEER spectra, Tikhonov fits and decomposed Gaussian fits are shown
for a) Cdk2:dinaciclib, b) Cdk2:AZD5438, c) Cdk2:roscovitine, d) Cdk2:flavopiridol.
e) All four inhibitors promote the Aloop-out2 state in the presence of cyclinA, as man-






























































































































































Figure 3.11: DEER spectra (bottom) and spin-spin distance distributions (top) for
Cdk2 bound to four Cdk2 inhibitors. Distance distributions were acquired by fitting
DEER spectra using Tikhonov regularization, and independently fitting to two Gaussian
functions representing αC-out and αC-in states. The distance distribution from the αC-
in state of Cdk2:K03861 is shown in grey and scaled along the y-axis for clarity. DEER
spectra, Tikhonov fits and decomposed Gaussian fits are shown for a) Cdk2:dinaciclib,
b) Cdk2:AZD5438, c) Cdk2:roscovitine, d) Cdk2:flavopiridol. e) All four inhibitors
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Figure 3.12: Allosteric two-state model for inhibitor binding to Cdk2, with K and
K∗ representing the Aloop-in and Aloop-out states of the kinase, D representing the





the microscopic equilibrium constants for inhibitor binding to Aloop-out and Aloop-in
states, respectively. The coupling parameter β describes the fold change in K eq upon
inhibitor binding. The bar graph summarizes the values of K eq and β derived from
Gaussian fits of the A-loop DEER data. Error bars represent 75% CIs, calculated from
50,000 simulations of Gaussian fits to the primary data.
Although dinaciclib and roscovitine have similar chemical structures, roscovitine
triggers a larger conformational shift. The x-ray structures of Cdk2 bound to dinaciclib
and roscovitine are nearly identical, with the notable exception of a 3.5 angstrom shift of
the ε-amino group of the catalytic lysine residue K33 (Figure 3.13)52,61. In the dinaciclib
structure, K33 forms a salt bridge with D145 of the catalytic DFG motif, but the larger
9-isopropyl substituent of roscovitine compared to the 3-ethyl group of dinaciclib causes
K33 to shift away from D145, breaking the salt bridge. Breakage of this salt bridge has
been linked to conformational transitions away from the CDK/Src-like inactive state77,
and may explain the larger shift triggered by roscovitine. A similar mechanism may also
explain the shift triggered by AZD5438, the 2-methylimidazole group of which, like the
9-isopropyl group of roscovitine, would clash with the position of the K33 lysine residue
48










DFG motif αL12 helix
PDB ID: 2A4L
PDB ID: 4KD1
Figure 3.13: Aligned crystal structures of Cdk2 bound to dinaciclib and roscovitine.












Figure 3.14: The x-ray structure of monomeric Cdk2 bound to AZD5438. The two con-
formations in the crystallographic model (PDB ID: 6GUH) are colored light blue for the
inactive state and dark blue for the active-like state. The position of the catalytic lysine
K33 in the corresponding dinaciclib structure is shown in light yellow for comparison.
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Flavopiridol promotes the Aloop-out/αC-in state by a different mechanism. In the
crystal structure of flavopiridol bound to the Cdk2:cyclinA dimer42, the inhibitor forms
hydrogen bonds with the K33 residue, the catalytic glutamate E51 and a water molecule
(Figure 3.15, left). Water-mediated hydrogen bond networks at this site are important
for catalytic function and inhibitor recognition78,79, and structures of Cdk2:cyclinA80
bound to nucleotides show a strikingly similar hydrogen bonding geometry (Figure 3.15,
right). In DEER experiments, ADP binding also promoted the Aloop-out state (Fig-
ure 3.8), suggesting that flavopiridol and nucleotide trigger conformational shifts by









Figure 3.15: Structures of Cdk2:cyclinA bound to flavopiridol and ADP shown side by
side. Hydrogen bonds are shown as yellow dashed lines, and structured water molecules
as red spheres.
We also obtained DEER spectra of the Cdk2:cyclinA complex bound to the Cdk4
inhibitors palbociclib, ribociclib and abemaciclib (Figure 3.16). Although we had ini-
tially anticipated that the inhibitors would stabilize the Aloop-in subpopulation due
to their tight binding to the inactive Cdk4:cyclinD complex, all three Cdk4 inhibitors
drove relatively subtle shifts to the Aloop-in conformation, with abemaciclib having the
largest effect. This was our first evidence that abemaciclib differs from the other two
50






























Figure 3.16: DEER experiments tracking the A-loop in the Cdk2:cyclinA:inhibitor com-
plexes of palbociclib, ribociclib and abemaciclib. Solid lines represent Tikhonov-derived
distance distributions, while dashed black lines represent the Gaussian fits to the DEER
data. Of the three inhibitors, abemaciclib drives the largest shift to the Aloop-out state.
3.2.2 Inhibitor and cyclin binding are allosterically coupled
Several Cdk2 inhibitors bind more tightly in the presence of the cyclin subunit42. To
simultaneously track inhibitor binding and conformational changes, we labeled Cdk2
with donor and acceptor dyes on the same sites used for conjugating spin labels for the
A-loop DEER experiments, yielding high FRET for the Aloop-in state and low FRET







Figure 3.17: Schematic of the Cdk2 FRET sensor. Alexa 488 (donor) and Alexa 568
(acceptor) were conjugated to the same sites as the DEER spin probes.
Titrations of cyclinA and Cdk2 inhibitors both resulted in decreased FRET, con-
sistent with shifts to the Aloop-out state (Figures 3.18 and 3.20), and the decrease
triggered by cyclinA was larger for phosphorylated than unphosphorylated Cdk2, in
agreement with the larger shift observed by DEER. The FRET data were analyzed by
global fitting to an extended allosteric two-state model (ATSM)36,81 (Figure 3.19) that
describes the binding of cyclin and inhibitor and the effects thereof on the equilibrium
between Aloop-in and Aloop-out states (see Methods). To map the FRET signal onto
the conformational equilibrium, the model was parameterized using the Aloop-in/out
equilibrium constants measured by DEER for apo and cyclin-bound Cdk2, thereby con-
straining the allosteric coupling parameter α. The resulting fits allowed the remaining
thermodynamic parameters of the model to be defined, including the microscopic equi-
librium constants for cyclin and inhibitor binding to Aloop-in and Aloop-out states, and
the allosteric coupling parameters α,γ and δ. The values of β obtained from the model
are similar to those measured by DEER and confirm that the Cdk2 inhibitors promote










































































Figure 3.18: FRET measurements for AZD5438 binding to Cdk2 (left) and pCdk2
(right) at different cyclinA concentrations. The black dashed lines are the global fit to
the allosteric model shown in Figure 3.19. The FRET values are shown on the right






















K = Cdk2 Aloop-in









Figure 3.19: The allosteric model used to fit the FRET data. The model describes
the binding of cyclin and inhibitor to the Aloop-in and Aloop-out states, with K eq
representing the Aloop-in/out equilibrium, K cyclineq and K
drug
eq representing microscopic
equilibrium constants for cyclin and inhibitor binding to the Aloop-out state, and the
allosteric allosteric coupling described with α, β, γ and δ. The Aloop-in/out equilibrium
is represented as a gray scale.
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Figure 3.20: FRET measurements of inhibitor binding. Inhibitor and cyclin binding
experiments with unphosophorylated Cdk2 (top) and phosphorylated Cdk2 (bottom).
Ratiometric FRET measurements from representative experiments are shown along with
the global fits (dashed black lines, see Methods).
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Figure 3.21: β values derived from fits of the FRET data to the extended allosteric two
state model (black) and the corresponding values independently measured with DEER
(blue), show that the four Cdk2 inhibitors drive a conformational shift to the Aloop-out
state. Values for FRET experiments are mean ± S.E.M; n = 3 independent experiments.
Several insights emerge from this analysis. First, cyclin affinity for the Aloop-out
state is enhanced ∼8-fold by phosphorylation (Figure 3.22). In contrast, phosphoryla-
tion has a modest effect on the affinity for cyclin binding to the Aloop-in state. This
explains why phosphorylation enhances the allosteric shift triggered by cyclin binding.
Second, the model recapitulates the positive binding cooperativity between cyclin and
the Cdk2 inhibitors42 and reveals that it can be partitioned into two allosteric effects,
quantified by the allosteric coupling parameters β and γ (Figures 3.23 & 3.24). These
can be understood as follows: the conformational shifts triggered by the inhibitors (β)
arise from higher binding affinity for the Aloop-out state; since this state predominates
when cyclin is bound, the inhibitor affinity is also enhanced by cyclin binding. How-
ever, even within the Aloop-out state there is allosteric cooperativity between inhibitor
and cyclin (γ). This may arise from overlapping effects of the two ligands on the ki-
nase conformational entropy, consistent with previous ITC experiments that showed a
smaller entropic penalty for AZD5438 binding to the Cdk2:cyclin dimer than monomeric
Cdk242. Together, the two allosteric effects give rise to strong binding cooperativity:
>10-fold in all four cases, and 50-fold for flavopiridol binding unphosphorylated Cdk2.
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Without this cooperativity, these molecules would lack sufficient potency to effectively

























 cyclin anity for state:
Figure 3.22: Microscopic equilibrium constants for cyclin binding to Aloop-in (αKcyclinD )
and Aloop-out (KcyclinD ) states of unphosphorylated and phosphorylated Cdk2. Values



























































Figure 3.23: Microscopic equilibrium constants for inhibitor binding to three different
structural states of unphosphorylated Cdk2. The arrow represents the allosteric coupling
effects that drive cooperative binding of inhibitor and cyclin. Values are mean ± s.e.m.;

































































Figure 3.24: Microscopic equilibrium constants for inhibitor binding to three different
structural states of phosphorylated Cdk2. The arrow represents the allosteric coupling
effects that drive cooperative binding of inhibitor and cyclin. Values are mean ± s.e.m.;
n = 3 independent experiments.
We also tested the Cdk4 inhibitors abemaciclib, palbociclib and ribociclib in our
FRET assay (Figures 3.23 & 3.24). Palbociclib and ribociclib are selective for Cdk4,
while abemaciclib inhibits both Cdk4 and Cdk262,71. Abemaciclib behaved like the Cdk2
inhibitors, promoting the Aloop-out state and exhibiting binding cooperativity with
cyclin that was similarly partitioned between β and γ effects, and without which the drug
would likely lack efficacy against Cdk2. In striking contrast, palbociclib and ribociclib
did not promote the Aloop-out state and lacked substantial binding cooperativity with
cyclin.
While the Cdk4 inhibitors palbociclib and ribociclib are readily distinguished from
the Cdk2 inhibitors by their weak affinities for the Cdk2:cyclinA dimer, the distinction
between the two classes of inhibitor becomes blurred when considering their binding
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affinities for the different conformational states of Cdk2. For example, the Cdk2 in-
hibitor roscovitine and the Cdk4 inhibitor ribociclib are predicted to bind with similar
affinity to the Aloop-in state of monomeric Cdk2, and the same holds for flavopiridol
and palbociclib. Thus, the clear separation between the Cdk4 and Cdk2 inhibitor classes
apparent in IC50 inhibition values (Figure 3.25) is attributable to the strong allosteric















































of Cdk2 and Cdk4 inhibitors 
Figure 3.25: The IC50 values of the seven inhibitors for the pCdk2:cyclinA dimer.
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3.3 Methods
FRET experiments tracking the A-loop
FRET samples were prepared by labeling “Cys-lite2” constructs of Cdk2 (C118A,
C177S, A93C, R157C) with a 0.7:1 ratio of donor (AF488, Fluoroprobes) followed by
a threefold excess of acceptor (AF568; Fluoroprobes) to ensure complete labeling. La-
beled samples were purified by size exclusion chromatography into 1X PBS pH 7.4, 10
mM MgCl2, 5 mM DTT and supplemented with 0.5 mg/ml bovine gamma globulins
(Sigma) and 0.02% Tween-20. Inhibitor dose response titrations were prepared in 384-
well plates using a mosquito liquid handling robot (ttp Labtech). Cdk2 FRET sensor
(24 µL) was added to each well containing 1 µL of inhibitor in DMSO and incubated
for 30 minutes prior to data collection. Steady-state fluorescence emission spectra were
recorded with a fluorescence plate reader (Fluorescence Innovations), and the contribu-
tions of the donor and acceptor emission peaks to the measured emission spectra were
unmixed by fitting each spectrum to basis functions for AF488, AF568 and the water
Raman band82. For each inhibitor, binding experiments were performed using eight
concentrations of cyclinA and twelve concentrations of inhibitor.
Global fit analysis of FRET data
FRET data were fit globally, using the numerical simulation package Kintek Explorer,
to the extended allosteric two state model36,81 shown in Figure 3.19. In this model,
KcyclinD and K
drug
D represent the microscopic equilibrium constants for binding to the
Aloop-out state of cyclinA and inhibitor, respectively, and αKcyclinD and βK
drug
D the






represents the conformational equilibrium constant for monomeric Cdk2, and α, β, γ,
and δ represent the allosteric coupling factors that describe the coupling between cyclin
binding and the conformational equilibrium (α), drug binding and the conformational
equilibrium (β), the binding cooperativity between cyclin and drug in the Aloop-out
state (γ) and the difference in binding cooperativity between the Aloop-in and Aloop-
out states (δ).
The measured ratiometric FRET signal FD/A was mapped onto the conformational
equilibrium using one fluorescence coefficient, c1, to represent the Aloop-in state, and
one coefficient, c2, for the Aloop-out state,
FD/A = c1 ∗ ([K] + [KC] + [KD] + [KDC]) + c2 ∗ ([K∗] + [K∗C] + [K∗D] + [K∗DC]) (3.2)
where K and K∗ represent monomeric Cdk2 in the Aloop-in and Aloop-out states,
respectively, KC and K∗C Cdk2:cyclinA in the Aloop-in and Aloop-out states, KD and
K∗D Cdk2:inhibitor in the Aloop-in and Aloop-out states, and KDC and K∗DC Cdk2
bound to both cyclinA and inhibitor in the Aloop-in and Aloop-out states. The values
of Keq and αKeq were constrained to their values measured in the DEER experiments
(Figures 2.15 and 3.26; Keq = 0.143 for Cdk2, Keq = 0.178 for pCdk2, αKeq = 1.26
for Cdk2:cyclinA and αKeq = 6.4 for pCdk2:cyclinA). For unphosphorylated Cdk2,
fitting yielded well-constrained values for all remaining parameters of the model (β,
γ, δ, KcyclinD and K
drug
D ) as judged by one- and two-dimensional error surface analysis
(Figure 3.27). For phosphorylated Cdk2, the value of the allosteric coupling parameter
δ, which determines the cyclin and inhibitor affinities for the inactive Aloop-in state
of the pCdk2:cyclin dimer, was not well constrained in some datasets. We therefore

























































































Figure 3.26: Gaussian populations derived from the DEER data for Cdk2 and
Cdk2:cyclinA were used to constrain the values of the equilibrium constants Keq and



















































































































































































































































































































































































































































































K = Cdk2 Aloop-in









Figure 3.27: Error surface analysis of global fitting of FRET data to the extended
allosteric two state model. A representative error surface analysis of the fit parameters
performed in Kintek Explorer. Every pairwise combination of unconstrained parameters
was explored and the ratio of the optimal fit χ2 (chi2min) to the χ2 obtained with a
given combination of parameters is plotted on a color scale as shown in the legend.
Chapter 4
Allostery manifest in the
architecture of Cdk2
4.1 Background
Despite a high degree of sequence conservation across the Cdk family (Figure 4.1), it
is clear that the individual CDKs have adopted disparate activation mechanisms to
regulate their activity. For example:
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               1         10        20          30        40 
Cdk2                            G G    V K            A K        M F V I  TYG  Y AR K T V L KIRL............... EN QK E..K E V N L G..EV DTET
Cdk3                            G G    V K            A K        M F V I  TYG  Y AK R T V L KIRL............... DM QK E..K E V N E G..QL DLEM
Cdk1                            G G    V K            A K        M Y I I  TYG  Y R K T V M KIRL............... ED TK E..K E V G H T G..QV ESEE
Cdk5                            G G    V K            A K        M Y L I  TYG  F AK R T V L RVRL............... QK EK E..K E T N E H..EI DDDD
Cdk4                            G G    V K            A K        Y V I  YG  Y AR S V L VRV.............MATSR EP A..E V A T DPH G..HF S PNGG
Cdk6                            G G    V K            A K        Y V I  YG  F AR N V L RVRV......MEKDGLCRADQQ EC A..E E A K DLK GG.RF QTGE
Cdk9                            G G    V K            A K        V Y L I  TFG  F AR R T V L KV MMAKQYDSVECPFCDE SK EK A..K Q E H K G..QK L ENEK
Cdk7                            G G    V K            A K        A Y L L  QF  Y AR K T V I KIKL.......MALDVKSR KR EK D..F E AT D N N..QI GHRS
Cdk8                            G G    V K            A K        V V  TYG  Y AK K  L IMDYDFKVKLSSERER EDLFEYEGCK R H R DGKDDKDY Q EG....
          50           60        70                80       
Cdk2     G      RE   L  L    H N   L                   L F     DLE VP TAI  I L K   P IV  DV T E KL  V EFL   ... S S E N... K L IH ........ N Y HQ
Cdk3     G      RE   L  L    H N   L                   L F     DLE VP TAI  I L K   P IV  DV N E KL  V EFL   ... S S E K... R L VH ........ R Y SQ
Cdk1     G      RE   L  L    H N   L                   L F     DLE VP TAI  I L K   P IV  DV Q D RL  I EFL   ... S S E R... S Q LM ........ S Y SM
Cdk5     G      RE   L  L    H N   L                   L F     DLE VP SAL  I L K    IV  DV S D KL  V EF   ... S C E K... K R H LH ........ K T CDQ
Cdk4     G      RE   L  L    H N   L                   L F     DL LP S V  V L R   P VV  DV T E KV  V E V   GGGG I T A R EAFE R M CA SRTDR... I T H DQ
Cdk6     G      RE   L  L    H N   L                   L F     DLE MP S I  V V R   P VV  DV E KL  V E V   ... L T A H ETFE R F CTVSRTDR... T T H DQ
Cdk9     G      RE   L  L    H N   L                   L F     DLE P TAL  I I    VV  EI T I  V DF   ... F I K QL K... E N I CR KASPYNRCKGS Y CEH
Cdk7     G      RE   L  L    H N   L                   L F     DLD I TAL  I L   P II  DA I  V DFM   EAK NR K QE S... G L FGH........KSN S ET
Cdk8     G      RE   L  L    H N   L                   L F     DL I SA   I L R   P VI  V S D KV  L DYA   ...T SM C A E K... S QK FL ......HA R W EH
 90              100       110       120       130          
Cdk2                         K      L G    H     HRD K  N L      M I I L QL  L F  VL   L P  L IKKF DASA.......LTG PLPL SY F Q A C SHR Q N....
Cdk3                         K      L G    H     HRD K  N L      M L I L QL  V F  VI   L P  L IKKY DSTP.......GSE PLHL SY F Q S C SHR Q N....
Cdk1                         K      L G    H     HRD K  N L      L M V L QI  I F  VL   L P  L IKKY DSIPP......GQY DSSL SY Y Q V C SRR Q D....
Cdk5                         K      L G    H     HRD K  N L      L V L QL  L F  VL   L P   IKKYFDSCN........GD DPEI SF F K G C SRN Q P N....
Cdk4                         K      L G    H     HRD K  N L      L L I M Q   L F  IV   L P  I VRTY DKAP.......PPG PAET DL R F R D L ANC E T....
Cdk6                         K      L G    H     HRD K  N L      L V I M QL  L F  VV   L P  I VTTY DKVP.......EPG PTET DM F R D L SHR Q T....
Cdk9                         K      L G    H     HRD K  N L      L I M L  L Y  IL   M  V IAGL SNVL........VKFTLSE RV QM N Y I RNK AA T....
Cdk7                         K      L G    H     HRD K  N L      I L I M   L Y  IL   L P  L LEVI KDNS........LV TPSH AY LMT Q E L QHW N D....
Cdk8                         K      L G    H     HRD K  N L      I L V L QI  I Y  VL   L P  I VWHI KFHRASKANKKPVQ PRGM SL Y D H L ANW A MGEGP
 140       150           160       170       180       190  
Cdk2   G  K AD G A                 VVT WYR P  L     Y    D W  G I I L  F L RAF V T    L    EI LG  V I L C TE A GVP R....TY HE A CKY STA S
Cdk3   G  K AD G A                 VVT WYR P  L     Y    D W  G I I L  F L RAF L T    L    EI LG  V I I C EL A GVP R....TY HE A SKF TTA S
Cdk1   G  K AD G A                 VVT WYR P  L     Y    D W  G I I L  F L RAF I T    L    EV LG  V I I  DK T GIP R....VY HE S SAR STP S T
Cdk5   G  K AD G A                 VVT WYR P  L     Y    D W  G I L L  F L RAF V S    L    DV G  I M A C RN E GIP R....CY AE P F AKL STS S
Cdk4   G  K AD G A                 VVT WYR P  L     Y    D W  G I V L  F L RIY M T    L    EV L  V M V C SG T SYQ .....AL PV A QST. ATP S
Cdk6   G  K AD G A                 VVT WYR P  L     Y    D W  G I I L  F L RIY M T    L    EV L  V L V C SS Q SFQ .....AL SV A QSS. ATP S
Cdk9   G  K AD G A                 VVT WYR P  L     Y    D W  G I L L  F L RAF T    L    EL LG  I L A C RD V SLAKNSQPNRY NR P ERD GPP G
Cdk7   G  K AD G A                 VVT WYR P  L     Y    D W  G I L L  F L K F T        EL G  V M V C EN V S GSPNR....AY HQ R A F ARM GVG A
Cdk8   G  K AD G A                 VVT WYR P  L     Y    D W  G I V I    RLF L        EL LG  I I I C ER R M F NSP KP.LADLDPV F A ARH TKA A
      200                210       220       230       240  
Cdk2  AE                         QL  I    G      W               F  M R LF G SE D  R F L P E  P V MPVT .RA P D .........I F RT T D VV G TS DYKPSFPK
Cdk3  AE                         QL  I    G      W               F  M R LF G SE D  R F ML P ED  P V LPVT .KA P D .........I F R T S T G TQ DYKGSFPK
Cdk1  AE                         QL  I    G      W               F  L K PLF G SE D  R F AL P E  P V LAT .K H D .........I F R T NN V E ES QDYKNTFPK
Cdk5  AE                         QL  I    G      W               F  L PLF G D  R F LL P EE  P M LPANAGR P NDV.........D K R T T Q S TK DYKP.YPM
Cdk4  AE                         QL  I    G      W               F  M R PLF G SE D  K F LI P ED  P LPFR .K C N .........A G D L P D RDVS ..RGAFPP
Cdk6  AE                         QL  I    G      W               F  M R PLF G SD D  K VI P EE  P LPFR .K R S .........V G LD L G D RDVA ..RQAFHS
Cdk9  AE                         QL  I    G      W                 M R PI TE    L  E  P VM WT .S MQAN .........QH AL SQ C SITP V N DNYELYEKLELV
Cdk7  AE                         QL  I    G      W                 L R P G SD D  R F L P EE  P M LPL LL .V FLP D .........L T ET T T Q D CS DYVTFKSF
Cdk8  AE                         QL  I    G      W               F  L PIF QE D  R F VM P D  I MPLTS.E HCR DIKTSNPYHH D N F A KD ED KK EHSTLMKD
          250           260       270       280       290   
Cdk2                             L        P  RI    A             V LD  L ML    S  L H FFWARQ.....DFSKV PP.... EDGRS SQ HYD NK AKA A P QDVTKPV
Cdk3                             L        P  RI    A             L V LE  L LL    T  L H YFWTRK.....G EEI PN.... PEGRD MQ QYD SQ AKT A P SSP.EPS
Cdk1                             L        P  RI    A             L V LD  L ML    S  L H YFWKPG.....S ASH KN.... ENGLD SK IYD AK GKM N P NDLDNQI
Cdk5                             L        P  RI    A             L V L  L LL    S  L H YFYPATT....S VNV PK.... NATGRD QN KCN VQ AEE Q P SDFCPP.
Cdk4                             L        P  RI    A             V V ME  L ML    S  L H YRGPR.....P QSV PE.... ESGAQ LE TFN HK AFR Q S LHKDEGNP
Cdk6                             L        P  RI    A             I V ID  L L    S  L H YFKSAQ.....P EKF TD.... ELGKD LKC TFN AK AYS S P QDLERCK
Cdk9                             L        P  RI    A             V L D  I LL     L H FFKGQKR....K KDR KAY..VR PYALD DK VLD AQ DSDD N D WSDPMPS
Cdk7                             L        P  RI    A             L A  I L    T  L YFPGIP...... HHIFSA.... GDDLLD QG FLFN CA ATQ KMK SNRPGPT
Cdk8                             L        P  RI    A             L M D  L LL    T  M YFFRRNTYTNCS IKY EKHKVKP SKAFH QK TMD IK SEQ QDP LEDPLPT
Figure 4.1: Sequence alignment of CDKs 1-9. Generated using [83] and [84].
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• CDKs have preferred cyclin binding partners, with canonical CDK:cyclin pairings
comprising vastly different binding interface surface areas11,24,85–87, and dictating
important signalling aspects such as cell cycle timing88 and substrate recogni-
tion89,90.
• CDKs differ in their requirement for non-cyclin accessory proteins for activation
(e.g. Cks proteins for Cdk191 or MAT1 for Cdk792).
• CDKs contain both activating and inactivating phosphorylation sites93, but they
vary in their requirement for phosphorylation to achieve a particular activation
state92, as well as in their ability to be continuously phosphorylated and dephos-
phorylated in cells.
• CDKs are known to associate with two different families of CDK-inhibitory pro-
teins (INK4 and CIP/KIP families) for additional control of kinase activity in the
cell cycle94,95.
Each of these topics comprises its own line of investigation spanning decades of work,
and is therefore largely beyond the scope of this study. However, each mechanism loosely
ties into the questions at hand: how does the architecture of the kinase itself regulate
its conformation and activity?
4.2 Results
4.2.1 The autoinhibitory hub of Cdk2 differs from that of Cdk4
The impetus for this study was the observation that, unlike in Cdk2, where cyclin
binding and phosphorylation are enough to drive the kinase into the active conforma-






Figure 4.2: X-ray structures depicting the pCdk2:cyclinA complex (1JST) in an active-
like conformation and the pCdk4:cyclinD complex (2W96) in the inactive conformation.
Since Cdk4 is not exempt from the requirement to adopt the active conformation in
order to perform catalysis, several studies have investigated other biochemical determi-
nants of Cdk4:cyclinD activation, pointing to both substrate89 and, paradoxically, the
CDK inhibitory protein p2796. In comparing the structures of human Cdk2 and Cdk4,
we noticed differences in a particular set of hydrophobic residues in the core of the ki-
nase (the “hub;” Figure (4.3), leading us to wonder how much they contribute to the
ability of cyclin and phosphorylation to activate the CDKs, how they affect substrate






















Figure 4.3: A comparison of the hydrophobic residues that comprise the autoinhibitory
“hub” of Cdk2 and Cdk4.
4.2.2 A divergent hub controls allosteric coupling in Cdk2
To investigate the origins of the distinct allosteric wiring of Cdk2 and Cdk4, we per-
formed a phylogenetic analysis of Cdk1, Cdk2 and the Cdk4/6 family across metazoan
lineages (Figure 4.4). Mapping the metazoan sequence conservation within the respec-
tive CDK families onto the structures of Cdk2 and Cdk4 in the Aloop-in state revealed
that the entire kinase domain interior was conserved in the Cdk1 and Cdk2 families, but
that there was a hotspot of conservative amino acid substitutions in Cdk4/6 clustered
in and around the αL12 helical turn of the A-loop (Figure 4.5). The variable residues
are hydrophobic and interact with one another across the interface between the αL12
helix and the N-terminal lobe (the “hub”). These interactions are broken when the
αL12 helix unfolds to form anchor 1 in the Aloop-out state. The residue at the center
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of the hub is on the αL12 helix and is strictly conserved as an alanine in Cdk1 and Cdk2
(A151 in human Cdk2). In vertebrate Cdk4/6, this residue is instead conserved as an
isoleucine (I164 in human Cdk4) and engages in more extensive hydrophobic interac-
tions with the rest of the hub than the corresponding alanine residue of Cdk2 (Figure
4.5). The isoleucine in vertebrate Cdk4/6 is substituted in more basal clades with either
valine or threonine (Figure 4.6). An enlarged β-branched residue at this position is thus


















Cdk1 (putative) Ixodes scapularis 
Cdk1-like Dendronephthya gigantea
Cdk1-like Acropora millepora
Cdk1 isoform X1 Nematostella vectensis





















































































































A151 in human Cdk2 
I164 in human Cdk4 
Figure 4.4: The phylogenetic tree was generated using the maximum likelihood method
in MEGA X. The amino acid residue found at the central hub location (A151 in human
Cdk2, I164 in human Cdk4)is shown for each species. There is a clear divergence of this


































Figure 4.5: Metazoan sequence conservation in Cdk1/2 (a) and Cdk4/6 (b), determined
from a set of 20 sequences (Figure 4.4) is mapped onto the structures of Cdk2 (left)
and Cdk4 (right) in the Aloop-in conformation. Red represents strict conservation and



















I164 in human Cdk4
A151 in human Cdk2
Figure 4.6: Divergence of the central hub residue (A151 in Cdk2, I164 in Cdk4) between
Cdk1/2 and Cdk4/6 lineages.
We prepared a mutant of Cdk2 in which five hub residues were replaced with those of
human Cdk4 (Cdk2cdk4hub; Figure 4.7). We also prepared a second mutant in which the
L148 residue was replaced with arginine to destabilize the hub (Cdk2L148R), inspired
by a similar oncogenic mutation in EGFR97. DEER experiments revealed opposite
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effects of these mutations on the kinase conformation (Figure 4.8). In the monomeric
form, the pCdk2cdk4hub mutant was fully in the Aloop-in state, with no evidence of the
Aloop-out subpopulation observed in WT Cdk2 (Figure 4.9). Addition of saturating
cyclinA resulted in the appearance of an Aloop-out subpopulation, but it remained the
minor population (19 ± 9 %). Results with the phosphorylated and unphosphorylated
Cdk2cdk4hub mutant were similar, indicating that phosphorylation was no longer coupled
to the structural change. Thus, the Cdk2cdk4hub mutant remains predominantly in the
Aloop-in state even when bound to cyclin and phosphorylated on the A-loop, as has
been reported for Cdk424,25. In contrast, monomeric pCdk2L148R displayed an increased
Aloop-out subpopulation compared to WT Cdk2, and addition of cyclinA resulted in
homogeneous adoption of the Aloop-out state with no evidence of a residual Aloop-
in subpopulation, unlike WT Cdk2 (Figure 4.10). The two sets of mutations also had
opposite effects on the affinity of cyclin binding measured by FRET (Figure 4.11). These
results demonstrate that the residues of the hub play an important role in controlling
the Aloop-in/out equilibrium and the degree to which cyclin binding is coupled to












































Figure 4.7: Validation of the Cdk2cdk4hub construct, phosphorylation, cyclinA binding
and folding. a) Mass spectrum of unphosphorylated and phosphorylated Cdk2cdk4hub
homogeneously labeled with 2 MTSSL spin labels (expected masses: 34439 Da and
34519 Da, respectively). b) Size exclusion chromatograms for spin-labeled monomeric
Cdk2cdk4hub (blue), MTSSL-labeledCdk2cdk4hub:cyclinA complex (green), and free cy-
clinA. The SDS-PAGE gel shows the fractions from the size exclusion run on the
Cdk2cdk4hub:cyclinA complex, confirming the formation of the 1:1 complex and demon-
strating the presence of excess cyclinA in the sample used for DEER experiments.
Protein samples used for reference Cdk2 and cyclinA markers (lanes 1 and 2) had been
previously validated. This analysis was performed on the sample used for the DEER
experiment.
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0.25 0.67 1.5 40
(α)Keq
75% CI
Figure 4.8: Conformational equilibrium values for WT Cdk2, pCdk2L148R and
pCdk2cdk4hub. Error bars represent 75% CIs, calculated from 50,000 simulations of
Gaussian fits to the primary data.
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Figure 4.9: DEER data for the phosphorylated pCdk2cdk4hub mutant.


















Figure 4.10: DEER data for the phosphorylated pCdk2L148R mutant. The monomer





























Figure 4.11: Cyclin binding affinities measured by FRET for WT Cdk2, Cdk2L148R and
Cdk2cdk4hub mutants. Values are mean ± s.e.m.; n = 3 independent experiments.
For the Cdk2cdk4hub mutant we also probed the effects of the hub mutations on
inhibitor affinities. The affinities of the Cdk2 inhibitors and abemaciclib for the cyclin-
bound mutant were markedly decreased compared to WT Cdk2, whereas the affinities
of the Cdk4 inhibitors were unaffected (Figure 4.12). Consequently, the discrimination
between the Cdk2 and Cdk4 inhibitor classes, so apparent with WT Cdk2, was dimin-
ished. These changes in affinity arise specifically from loss of allosteric coupling with the
cyclin subunit, as they were not observed with the monomeric Cdk2cdk4hub mutant (Fig-
ure 4.13). We measured IC50 values for all 7 inhibitors against both pCdk2:cyclinA and
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pCdk4:cyclinD. The IC50 values obtained for Cdk2 show the expected >20-fold discrim-
ination between the Cdk2 and Cdk4 inhibitors (Figure 4.14), but the values measured
for Cdk4 show a strikingly different pattern. As expected, palbociclib, ribociclib and
abemaciclib inhibit Cdk4 potently, but so do the majority of the Cdk2 inhibitors. With
the exception of roscovitine, the Cdk2 inhibitors inhibit Cdk4 with IC50 values within
10-fold of palbociclib and ribociclib. Unlike Cdk2, Cdk4 does not differentiate clearly
between Cdk2 and Cdk4 inhibitors. Thus, by uncoupling cyclin binding from the struc-
tural change, the altered hub residues of Cdk4 have also removed a major mechanism















































Figure 4.12: Inhibitor KD values measured by FRET for WT pCdk2–cyclinA and













































Figure 4.13: Inhibitor KD values measured by FRET for WT pCdk2 and pCdk2
cdk4hub.





























































































Figure 4.14: IC50 values measured in kinase assays for the seven inhibitors for
pCdk2–cyclinA (left) and pCdk4–cyclinD (right). The shaded areas represent the range
of IC50 values within tenfold of the IC50 values for palbociclib and ribociclib. Values
are mean ± s.e.m.; n = 3 independent experiments.
In kinase assays, WT Cdk2, the Cdk2cdk4hub mutant, and Cdk4 itself showed similar
KM values toward the physiological substrate RB (Figure 4.15). However, the KM
value of Cdk4 for a short peptide substrate was 8-fold higher than that of Cdk2, and
the KM value of the Cdk2
cdk4hub mutant was in between that of WT Cdk2 and Cdk4.
This is likely attributable to Cdk4 and the Cdk2cdk4hub mutant favoring the Aloop-
in state, in which the peptide binding site is disassembled. In DEER experiments
with the Cdk2cdk4hub mutant, the addition of the short peptide substrate increased the
population of the Aloop-out3 state (Figure 4.16). This indicates that when binding to
the Cdk2cdk4hub mutant, and presumably to Cdk4 itself, substrates pay an energetic
penalty to induce the Aloop-out3 state, leading to compromised substrate recognition.
RB possesses a secondary docking site specific for Cdk4 and essential for phosphorylation
by Cdk4, but not Cdk289. A central function of this site may be to compensate for the
intrinsically poor substrate binding of Cdk4, driving the comparative specialization of









































Figure 4.15: KM values for phosphorylation of a short peptide substrate (left) and RB
(right), measured for WT pCdk2, pCdk2cdk4hub and pCdk4. Values are mean ± S.E.M;
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pCdk2








Figure 4.16: DEER data for the Cdk2cdk4hub mutant bound to cyclinA with and without
addition of saturating peptide substrate and AMPPNP.
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4.3 Methods
Protein expression and purification
Cdk2 constructs were prepared as detailed in chapter 2. The Cdk2cdk4hub mutant con-
tained the I35V, I52V, L76V, A151I and F152Y mutations derived from the sequence
of human Cdk4.
Human RB (residues 771-928 in a PGEX-3T vector) was expressed overnight in BL21
(DE3) Escherichia coli. Harvested cells were resuspended in 1X PBS, 10% glycerol, 1
mM DTT, pH 7.4, lysed with a homogenizer, and lysates clarified by centrifugation at
20,000 rpm. Clarified lysate was loaded onto 2 5mL GSTrap columns (GE), washed
with 1X PBS, 10% glycerol, 1 mM DTT, pH 7.4, and eluted with 50 mM Tris, 10%
glycerol, 20 mM reduced glutathione, 5 mM DTT, pH 8. Eluted protein was desalted
into 20 mM sodium phosphate pH 7.4, loaded onto 2 5 mL SP columns and eluted with
20 mM sodium phosphate, 1 M NaCl, pH 7.4.
Kinase activity assays
Kinase activities of WT and mutant recombinant pCdk2–cyclinA and commercial pCdk4:cyclinD
(Thermo Fisher) were determined using the ADP Quest accumulation assay (Eurofins).
Reactions were performed with 5 nM kinase and 200 µM ATP in 384-well plates us-
ing a fluorescence plate reader and the Magellan Standard software (Tecan) at 20 °C.
Rates were determined from time-dependent fluorescence traces by linear regression
using Prism 8 (Graphpad).
Reactions were performed in the presence and absence of substrate, and rates were
corrected for nonspecific ATP turnover by subtracting the rates measured in the ab-
sence of substrate. Substrates used include RB residues 771–928, which includes the
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C-terminal Cdk4 docking site, and the histone H1-derived short peptide substrate PK-
TPKKAKKL99,100. IC50 values for the seven inhibitors were measured using a γ-
33P




In cycling cells, monomeric Cdk2 is subject to a continuous cycle of phosphorylation
and dephosphorylation on T16088. Our results show that regardless of its phosphory-
lation state, monomeric Cdk2 samples the Aloop-out1 conformation that is optimized
for dephosphorylation rather than for substrate binding, thereby avoiding any residual
kinase activity arising from the Aloop-out subpopulation. This permits a small energy
barrier for the global structural change, promoting facile regulation while preventing
kinase activity from being uncoupled from the expression of cyclins A and E in G1 and
S phase. The effects of T160 phosphorylation are only unmasked in the presence of the
cyclin subunit, where it enhances the cyclin-driven conformational shift and favors the
Aloop-out3 state, trapping the kinase in the catalytically active form. This explains why
cyclin binding renders Cdk2 resistant to dephosphorylation in cells, a property that is
thought to be important for switch-like activation of the kinase at the G1/S boundary23.
In contrast, the graded activation of Cdk4 by growth factor signaling has been linked to
the A-loop phosphorylation site remaining accessible to both CAK and phosphatases in
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Cdk4:cyclinD complexes23. Our results with the Cdk2cdk4hub mutant suggest that this
is due to the altered allosteric wiring of Cdk4, in which the cyclin-driven conformational
shift is reduced and the enhancement of this shift by A-loop phosphorylation, observed
in Cdk2, is lost. The resulting disassembly of the peptide binding site in Cdk4:cyclinD
complexes also leads to weak activity toward generic substrates and dependence on the
secondary docking site of RB. We have traced the contrasting allosteric properties of
Cdk2 and Cdk4 to evolutionary divergence within the allosteric hub, and shown that
these differences have important implications for inhibitor recognition.
The advent of Cdk4 inhibitors transformed the treatment of hormone-responsive
breast cancer70,101, but the clinical experience with Cdk2 inhibitors has been less fa-
vorable. This has been attributed in part to the greater selectivity and therapeutic
window of Cdk4 inhibitors. Our results show that the active sites of Cdk2 and Cdk4 do
not inherently differentiate between Cdk2 and Cdk4 inhibitors. Instead, the distinction
between these two drug classes arises from their differential recognition of particular con-
formational states. The allosteric properties of the Cdk2 inhibitors reflect the fact that
cyclin binding is tightly coupled to the Aloop-out/αC-in state in Cdk2. By similarly
coupling to this conformational state, Cdk2 inhibitors are able to target the catalyti-
cally active Cdk2:cyclin complexes with high affinity despite binding monomeric Cdk2
relatively weakly. The Cdk4 inhibitors palbociclib and ribociclib are not allosterically
coupled in this way because cyclin binding is not tightly coupled to the structural change
in Cdk4. This lack of allosteric coupling ensures that palbociclib and ribociclib bind
both monomeric Cdk2 and Cdk2:cyclin complexes weakly, and is likely the result of
the development process of these drugs in which selectivity for Cdk4 over Cdk2 was
prioritized67,68. The importance of allostery is underscored by the contrasting example
of abemaciclib, which has greater potency for Cdk4 than either palbociclib or ribociclib,
but possesses the allosteric properties of a Cdk2 inhibitor and consequently targets Cdk2
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as well. This ability of abemaciclib to target CDKs other than Cdk4/6 has been asso-
ciated with a superior cytotoxicity profile and the ability to override clinical resistance
to palbociclib arising from overexpression of cyclinE71.
The allosteric effects of the Cdk2 inhibitors and abemaciclib have implications for
CDK scaffolding interactions, analogous to those reported for palbociclib96. The cognate
pairing of CDK and cyclin subunits is relatively labile in cells. For example, enhanc-
ing or blocking A-loop phosphorylation of Cdk1 shunts cyclinA onto Cdk1 or cyclinB
onto Cdk2, respectively88. The enhancement of cyclinA affinity by Cdk2 inhibitors is
likely to apply to other cyclin subunits, which could become sequestered in non-cognate
Cdk2:cyclin complexes. Sequestration of cyclinB in such a manner may explain why
abemaciclib blocks Cdk1 substrate phosphorylation and triggers a G2 arrest in cells71
despite lacking potent activity against Cdk1 in vitro62. Thus, the contrasting allosteric
properties of Cdk4 and Cdk2 inhibitors reported here may play a central role in the
therapeutic efficacy of these drugs.
5.2 The role of cyclins in the conformational balance of
CDKs
CyclinE associates with Cdk2 to drive the G1-S transition in the cell cycle, and the
Cdk2:cyclinE binding interface is larger than that of Cdk2:cyclinA102,103. This raises
the questions of whether the two cyclins differ in their ability to activate Cdk2 and
whether inhibitors would bind differently to the Cdk2:cyclinE complex. Furthermore,
the elucidation of the effects of the low molecular weight isoform of cyclinE21 by the
allosteric two-state model (ATSM) would serve as an instructive comparison for how
cyclinE activates its CDK partner.
For all of the experiments in this study, we were only able to use cyclinA. This
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was in large part due to the relative ease with which we could express, purify and
store monomeric cyclinA. It is unlikely that recombinant expression of other cyclins in
a monomeric form is an insurmountable problem, and therefore the effect of the other
cyclins warrants further study.
Although CDKs have preferences for which cyclins they bind to, they are known
to form noncanonical binding interactions with other members of the cyclin family,
particularly in pathological contexts. This, too, would make for an interesting line
of investigation: the ATSM treatment applied to various combinations of CDK and
cyclin partners would provide a detailed insight into how the specific interactions at the
CDK-cyclin interface contribute to CDK activation. It is likely that in addition to the
variable timing of cyclin expression in the cell, each cyclin may also be characterized by
a different α value.
5.3 The importance of considering the conformational equi-
librium in drug discovery
One of the key insights from this study is the variability in the degree to which active
site inhibitors are allosterically coupled to the conformational equilibrium of Cdk2.
The development of kinase inhibitors typically involves a process of winnowing drug
candidates through molecular docking and compound screening, followed by an iterative
optimization process by which substituents on a lead compound are modified and tested
against kinase activity. This is inherently a flawed process: in the case of Cdk2, for
example, the active pCdk2:cyclinA complex against which drug candidates are tested
happens to be locked in the most rigid conformational state the kinase is capable of
achieving. This process selects for inhibitors in an unfortunate way: not only does
it come at the expense of compounds that would bind tightly to an inactive state
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of the kinase, but it also exacerbates the problem of selectivity because the active
conformation, the one which permits every kinase to catalyze exactly the same reaction,
is naturally the one that is most highly conserved across the kinome. It is therefore
unsurprising that Cdk2 inhibitors such as dinaciclib have virtually indistinguishable
IC50 values for both Cdk1 and Cdk2, which likely limits the dosing regimen (and thus
limits efficacy) so as to avoid Cdk1-associated cytotoxicity in clinical trials.
In hindsight, it is also not surprising that Cdk4 inhibitors were the first (and to
this day, only) CDK inhibitors to be approved for clinical use. In this case, the typical
inhibitor development process described above was unknowingly aided by a quirk specific
to the drug target itself: unlike in pCdk2:cyclinA, the conformational balance of the
pCdk4:cyclinD complex is highly skewed towards the inactive conformation, thereby
making it possible to select for inhibitors (i.e. palbociclib, ribociclib and to a lesser
degree, abemaciclib) that are agnostic to the conformation of the kinase. Note that
while this analysis could easily be read as a dismissal of Cdk4 inhibitor development
as “easy,” it is not intended as such; the selectivity profiles of palbociclib, ribociclib
and abemaciclib are truly remarkable, and their availability helped provide us with
important insights into how kinase inhibitors truly interact with their targets.
Nevertheless, the explicit consideration of the conformational states of drug targets
is a necessity in any drug discovery pipeline, and the FRET assays in this study, as
well as prior work from our lab on Aurora A76, have laid a foundation for achieving
this. Compound screens that measure the structural states of drug targets in addi-
tion to biological activity may very well lead to drug candidates that would otherwise
never have been identified in a screen for activity alone. Knowledge of the ability of
inhibitors to interact with the kinase conformational equilibrium also has another im-
portant consequence: many researchers use inhibitors as controls, or as a means to
achieve a precondition for studies of other effects in cells (e.g. using a CDK inhibitor to
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block cell cycle progression). It is eminently possible to introduce confounding variables
(e.g. sequestration of other cyclins by the inhibitor-bound CDK) without realizing it.
The added dimension of conformational data would allow researchers to better account
for the unintended effects of inhibitor treatment.
Finally, there are significant efforts underway to develop “true” allosteric inhibitors
of Cdk2 that bind away from the active site104,105. Theoretically, these inhibitors would
be more selective for Cdk2 because they target pockets that are less conserved than
the active site. An ATSM analysis of Cdk2 in the presence of allosteric drug candi-
dates is critical, and may very well uncover molecules that are negatively cooperative
with cyclins (i.e. having β < 1), thus circumventing problems associated with cyclin
sequestration by Cdk2:inhibitor complexes.
5.4 Towards an understanding of the role of hub mutations
in the evolution of the eukaryotic cell cycle
There is a fascinating tension between the requirement for cellular signalling sensitiv-
ity, which allows the cell to respond to small changes in the environment, and the
requirement for robustness, which allows the cell to absorb the effects of genetic and en-
vironmental aberrations. There are dramatic examples of each extreme: relatively small
changes in PKCα kinase activity have been shown to propagate to disastrous effect in an
Alzheimer’s model106. In contrast, it has also been shown that a single Cdk:cyclin com-
plex can drive the whole cell cycle in fission yeast107, thus demonstrating the significant
redundancy built into the eukaryotic cell cycle. The link between particular somatic
point mutations and the resulting constitutively active kinases have been well studied
in cancer108,109, but the effects (if any) of many subtle mutations remain unknown.
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Although the Cdk2cdk4hub mutations resulted in dramatic changes in kinase con-
formation, inhibitor recognition, and catalytic activity, the Cdk2cdk4hub construct only
represents a difference of five residues between human Cdk2 and Cdk4. Our sequence
analysis of Cdk4 across different lineages uncovered a variety of conservative mutations
of hydrophobic residues in the hub; their effects on the conformation and catalytic ac-
tivity of the kinase, cell cycle timing, and their ultimate role in the evolution of the
eukaryotic cell cycle remain to be seen.
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50. Havĺıček, L. et al. Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Syn-
thesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds.
J. Med. Chem. 40, 408–412. issn: 0022-2623. https://doi.org/10.1021/
jm960666x (Feb. 1, 1997).
51. Khalil, H. S., Mitev, V., Vlaykova, T., Cavicchi, L. & Zhelev, N. Discovery and
development of Seliciclib. How systems biology approaches can lead to better drug
performance. Journal of Biotechnology. Progress in Biotechnology: EuroBiotech
2014 202, 40–49. issn: 0168-1656. https://www.sciencedirect.com/science/
article/pii/S0168165615000942 (May 20, 2015).
52. Azevedo, W. F. D. et al. Inhibition of Cyclin-Dependent Kinases by Purine Ana-
logues. European Journal of Biochemistry 243, 518–526. issn: 1432-1033. https:
//febs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1432-1033.1997.
0518a.x (1997).
53. Bettayeb, K. et al. CR8, a potent and selective, roscovitine-derived inhibitor
of cyclin-dependent kinases. Oncogene 27, 5797–5807. issn: 1476-5594 (Oct. 2,
2008).
54. Le Tourneau, C. et al. Phase I evaluation of seliciclib (R-roscovitine), a novel
oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
European Journal of Cancer 46, 3243–3250. issn: 0959-8049. https://www.
sciencedirect.com/science/article/pii/S0959804910007823 (Dec. 1, 2010).
55. Paruch, K. et al. Discovery of Dinaciclib (SCH 727965): A Potent and Selec-
tive Inhibitor of Cyclin-Dependent Kinases. ACS Med. Chem. Lett. 1, 204–208.
issn: 1948-5875, 1948-5875. http://pubs.acs.org/doi/10.1021/ml100051d
(Aug. 12, 2010).
56. Parry, D. et al. Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent
Kinase Inhibitor. Mol Cancer Ther 9, 2344–2353. issn: 1535-7163, 1538-8514.
https://mct.aacrjournals.org/content/9/8/2344 (Aug. 1, 2010).
57. Mita, M. M. et al. Randomized phase II trial of the cyclin-dependent kinase in-
hibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast
cancer. Clin Breast Cancer 14, 169–176. issn: 1938-0666 (June 2014).
96
58. Stephenson, J. J. et al. Randomized phase 2 study of the cyclin-dependent kinase
inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell
lung cancer. Lung Cancer 83, 219–223. issn: 1872-8332 (Feb. 2014).
59. Ghia, P. et al. Efficacy and safety of dinaciclib vs ofatumumab in patients with
relapsed/refractory chronic lymphocytic leukemia. Blood 129, 1876–1878. issn:
0006-4971. https://doi.org/10.1182/blood- 2016- 10- 748210 (Mar. 30,
2017).
60. Flynn, J. et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with sig-
nificant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
Leukemia 29, 1524–1529. issn: 1476-5551. https://www.nature.com/articles/
leu201531 (July 2015).
61. Martin, M. P., Olesen, S. H., Georg, G. I. & Schönbrunn, E. Cyclin-Dependent
Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of
Bromodomains. ACS Chem. Biol. 8, 2360–2365. issn: 1554-8929. https://doi.
org/10.1021/cb4003283 (Nov. 15, 2013).
62. Chen, P. et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical
Performance. Molecular Cancer Therapeutics 15, 2273–2281. issn: 1535-7163,
1538-8514. http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.
MCT-16-0300 (Oct. 1, 2016).
63. Anderson, M. et al. Imidazoles: SAR and development of a potent class of cyclin-
dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 18, 5487–
5492. issn: 0960-894X. https://www.sciencedirect.com/science/article/
pii/S0960894X08010792 (Oct. 15, 2008).
64. Byth, K. F. et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases
1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in
human tumor xenografts. Mol Cancer Ther 8, 1856–1866. issn: 1535-7163, 1538-
8514. https://mct.aacrjournals.org/content/8/7/1856 (July 1, 2009).
65. Boss, D. S. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of
the oral cyclin-dependent kinase inhibitor AZD5438 when administered at inter-
mittent and continuous dosing schedules in patients with advanced solid tumours.
Annals of Oncology 21, 884–894. issn: 0923-7534. https://www.sciencedirect.
com/science/article/pii/S0923753419389355 (Apr. 1, 2010).
66. Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo
for treatment of hormone-receptor-positive, HER2-negative metastatic breast can-
cer that progressed on previous endocrine therapy (PALOMA-3): final analysis
of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet
97
Oncology 17, 425–439. issn: 1470-2045. https://www.sciencedirect.com/
science/article/pii/S1470204515006130 (Apr. 1, 2016).
67. VanderWel, S. N. et al. Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of
Cyclin-Dependent Kinase 4. J. Med. Chem. 48, 2371–2387. issn: 0022-2623.
https://doi.org/10.1021/jm049355+ (Apr. 1, 2005).
68. Toogood, P. L. et al. Discovery of a Potent and Selective Inhibitor of Cyclin-
Dependent Kinase 4/6. J. Med. Chem. 48, 2388–2406. issn: 0022-2623. https:
//doi.org/10.1021/jm049354h (Apr. 1, 2005).
69. Lu, H. & Schulze-Gahmen, U. Toward understanding the structural basis of
cyclin-dependent kinase 6 specific inhibition. J Med Chem 49, 3826–3831. issn:
0022-2623 (June 29, 2006).
70. Hortobagyi, G. N. et al. Ribociclib as First-Line Therapy for HR-Positive, Ad-
vanced Breast Cancer. New England Journal of Medicine 375, 1738–1748. issn:
0028-4793. https://doi.org/10.1056/NEJMoa1609709 (Nov. 3, 2016).
71. Hafner, M. et al. Multiomics Profiling Establishes the Polypharmacology of FDA-
Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.
Cell Chemical Biology 26, 1067–1080.e8. issn: 2451-9456, 2451-9448. http://
www.cell.com/cell-chemical-biology/abstract/S2451-9456(19)30174-6
(Aug. 15, 2019).
72. Taylor-Harding, B. et al. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor
resistance via activation of E2F and ETS. Oncotarget 6, 696–714. issn: 1949-2553
(Jan. 20, 2015).
73. Herrera-Abreu, M. T. et al. Early Adaptation and Acquired Resistance to CDK4/6
Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res 76, 2301–
2313. issn: 1538-7445 (Apr. 15, 2016).
74. Dickler, M. N. et al. MONARCH1: Results from a phase II study of abemaciclib, a
CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast
cancer, after chemotherapy for advanced disease. JCO 34, 510–510. issn: 0732-
183X. https://ascopubs.org/doi/abs/10.1200/jco.2016.34.15_suppl.510
(May 20, 2016).
75. Gelbert, L. M. et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219:
in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combina-
tion with gemcitabine. Invest New Drugs 32, 825–837. issn: 1573-0646. https:
//doi.org/10.1007/s10637-014-0120-7 (Oct. 1, 2014).
98
76. Lake, E. W. et al. Quantitative conformational profiling of kinase inhibitors
reveals origins of selectivity for Aurora kinase activation states. PNAS 115,
E11894–E11903. issn: 0027-8424, 1091-6490. https://www.pnas.org/content/
115/51/E11894 (Dec. 18, 2018).
77. Levinson, N. M. et al. A Src-Like Inactive Conformation in the Abl Tyrosine
Kinase Domain. PLOS Biology 4, e144. issn: 1545-7885. https://journals.
plos.org/plosbiology/article?id=10.1371/journal.pbio.0040144 (May 2,
2006).
78. Levinson, N. M. & Boxer, S. G. A conserved water-mediated hydrogen bond
network defines bosutinib’s kinase selectivity. Nature Chemical Biology 10, 127–
132. issn: 1552-4469. https://www.nature.com/articles/nchembio.1404
(Feb. 2014).
79. Cyphers, S., Ruff, E. F., Behr, J. M., Chodera, J. D. & Levinson, N. M. A
water-mediated allosteric network governs activation of Aurora kinase A. Nature
Chemical Biology 13, 402–408. issn: 1552-4469. https://www.nature.com/
articles/nchembio.2296 (Apr. 2017).
80. Bao, Z. Q., Jacobsen, D. M. & Young, M. A. Briefly Bound to Activate: Transient
Binding of a Second Catalytic Magnesium Activates the Structure and Dynamics
of CDK2 Kinase for Catalysis. Structure 19, 675–690. issn: 0969-2126. http:
//www.cell.com/structure/abstract/S0969-2126(11)00132-8 (May 11,
2011).
81. Hall, D. A. Modeling the Functional Effects of Allosteric Modulators at Phar-
macological Receptors: An Extension of the Two-State Model of Receptor Ac-
tivation. Mol Pharmacol 58, 1412–1423. issn: 0026-895X, 1521-0111. https :
//molpharm.aspetjournals.org/content/58/6/1412 (Dec. 1, 2000).
82. Schaaf, T. M., Peterson, K. C., Grant, B. D., Thomas, D. D. & Gillispie, G. D.
Spectral Unmixing Plate Reader: High-Throughput, High-Precision FRET Assays
in Living Cells. SLAS DISCOVERY: Advancing the Science of Drug Discovery
22, 250–261. issn: 2472-5552. https://doi.org/10.1177/1087057116679637
(Mar. 1, 2017).
83. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple se-




84. Robert, X. & Gouet, P. Deciphering key features in protein structures with the
new ENDscript server. Nucleic Acids Research 42, W320–W324. issn: 0305-1048.
https://doi.org/10.1093/nar/gku316 (W1 July 1, 2014).
85. Echalier, A., Endicott, J. A. & Noble, M. E. M. Recent developments in cyclin-
dependent kinase biochemical and structural studies. Biochimica et Biophysica
Acta (BBA) - Proteins and Proteomics. Inhibitors of Protein Kinases 1804, 511–
519. issn: 1570-9639. https://www.sciencedirect.com/science/article/
pii/S157096390900291X (Mar. 1, 2010).
86. Brown, N. R. et al. CDK1 structures reveal conserved and unique features of
the essential cell cycle CDK. Nature Communications 6, 6769. issn: 2041-1723.
https://www.nature.com/articles/ncomms7769 (Apr. 13, 2015).
87. Greber, B. J. et al. The cryoelectron microscopy structure of the human CDK-
activating kinase. PNAS 117, 22849–22857. issn: 0027-8424, 1091-6490. https:
//www.pnas.org/content/117/37/22849 (Sept. 15, 2020).
88. Merrick, K. A. et al. Distinct Activation Pathways Confer Cyclin-Binding Speci-
ficity on Cdk1 and Cdk2 in Human Cells. Molecular Cell 32, 662–672. issn: 1097-
2765. http://www.sciencedirect.com/science/article/pii/S1097276508007636
(Dec. 5, 2008).
89. Topacio, B. R. et al. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the
Retinoblastoma Protein’s C-Terminal Helix. Molecular Cell 74, 758–770.e4. issn:
1097-2765. https://www.sciencedirect.com/science/article/pii/S1097276519302242
(May 16, 2019).
90. Takeda, D. Y., Wohlschlegel, J. A. & Dutta, A. A Bipartite Substrate Recogni-
tion Motif for Cyclin-dependent Kinases *. Journal of Biological Chemistry 276.
Publisher: Elsevier, 1993–1997. issn: 0021-9258, 1083-351X. https://www.jbc.
org/article/S0021-9258(18)46703-8/abstract (Jan. 19, 2001).
91. Patra, D., Wang, S. X., Kumagai, A. & Dunphy, W. G. The Xenopus Suc1/Cks
Protein Promotes the Phosphorylation of G2/M Regulators*. Journal of Biologi-
cal Chemistry 274, 36839–36842. issn: 0021-9258. https://www.sciencedirect.
com/science/article/pii/S0021925819530307 (Dec. 24, 1999).
92. Fisher, R. P., Jin, P., Chamberlin, H. M. & Morgan, D. O. Alternative mechanisms
of CAK assembly require an assembly factor or an Activating Kinase. Cell 83,
47–57. issn: 00928674. https://linkinghub.elsevier.com/retrieve/pii/
0092867495902333 (Oct. 1995).
100
93. Gu, Y., Rosenblatt, J. & Morgan, D. O. Cell cycle regulation of CDK2 activity by
phosphorylation of Thr160 and Tyr15. EMBO J 11, 3995–4005. issn: 0261-4189
(Nov. 1992).
94. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators
of G1-phase progression. Genes Dev. 13, 1501–1512. issn: 0890-9369, 1549-5477.
http://genesdev.cshlp.org/content/13/12/1501 (June 15, 1999).
95. Besson, A., Dowdy, S. F. & Roberts, J. M. CDK Inhibitors: Cell Cycle Regula-
tors and Beyond. Developmental Cell 14, 159–169. issn: 1534-5807. https://
www.sciencedirect.com/science/article/pii/S1534580708000415 (Feb. 12,
2008).
96. Guiley, K. Z. et al. p27 allosterically activates cyclin-dependent kinase 4 and an-
tagonizes palbociclib inhibition. Science 366. issn: 0036-8075, 1095-9203. http:
//science.sciencemag.org/content/366/6471/eaaw2106 (Dec. 13, 2019).
97. Paez, J. G. et al. EGFR Mutations in Lung Cancer: Correlation with Clinical
Response to Gefitinib Therapy. Science 304, 1497–1500. issn: 0036-8075, 1095-
9203. https://science.sciencemag.org/content/304/5676/1497 (June 4,
2004).
98. Chi, Y. et al. Identification of CDK2 substrates in human cell lysates. Genome
Biology 9, R149. issn: 1474-760X. https://doi.org/10.1186/gb-2008-9-10-
r149 (Oct. 13, 2008).
99. Hagopian, J. C. et al. Kinetic Basis for Activation of CDK2/Cyclin A by Phospho-
rylation. Journal of Biological Chemistry 276, 275–280. issn: 0021-9258, 1083-
351X. https://www.jbc.org/article/S0021-9258(18)44235-4/abstract
(Jan. 5, 2001).
100. Stevenson-Lindert, L. M., Fowler, P. & Lew, J. Substrate Specificity of CDK2-
Cyclin A WHAT IS OPTIMAL? J. Biol. Chem. 278, 50956–50960. issn: 0021-
9258, 1083-351X. http://www.jbc.org/content/278/51/50956 (Dec. 19,
2003).
101. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in com-
bination with letrozole versus letrozole alone as first-line treatment of oestrogen
receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-
18): a randomised phase 2 study. The Lancet Oncology 16, 25–35. issn: 1470-
2045, 1474-5488. http://www.thelancet.com/journals/lanonc/article/
PIIS1470-2045(14)71159-3/abstract (Jan. 1, 2015).
102. Lolli, G. Structural dissection of cyclin dependent kinases regulation and protein
recognition properties. Cell Cycle 9, 1551–1561. issn: 1551-4005 (Apr. 15, 2010).
101
103. Honda, R. et al. The structure of cyclin E1/CDK2: implications for CDK2 ac-
tivation and CDK2-independent roles. EMBO J 24, 452–463. issn: 0261-4189
(Feb. 9, 2005).
104. Betzi, S. et al. Discovery of a potential allosteric ligand binding site in CDK2.
ACS Chem Biol 6, 492–501. issn: 1554-8937 (May 20, 2011).
105. Christodoulou, M. S. et al. Probing an Allosteric Pocket of CDK2 with Small
Molecules. ChemMedChem 12, 33–41. issn: 1860-7187 (Jan. 5, 2017).
106. Callender, J. A. et al. Protein kinase Cα gain-of-function variant in Alzheimer’s
disease displays enhanced catalysis by a mechanism that evades down-regulation.
PNAS 115, E5497–E5505. issn: 0027-8424, 1091-6490. https://www.pnas.org/
content/115/24/E5497 (June 12, 2018).
107. Gutiérrez-Escribano, P. & Nurse, P. A single cyclin–CDK complex is sufficient
for both mitotic and meiotic progression in fission yeast. Nature Communications
6, 6871. issn: 2041-1723. http://www.nature.com/articles/ncomms7871
(Apr. 20, 2015).
108. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417,
949–954. issn: 0028-0836 (June 27, 2002).
109. Lynch, T. J. et al. Activating Mutations in the Epidermal Growth Factor Receptor
Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New
England Journal of Medicine 350, 2129–2139. issn: 0028-4793. https://doi.
org/10.1056/NEJMoa040938 (May 20, 2004).
Appendix A
A brief comparison of Cdk2 and
AurA DEER results
An important consideration in measuring effects of inhibitors on kinase conformation is
the value of context. A single DEER measurement will provide a distance distribution
for a sample, but it is extremely difficult to extract meaning from a single distance
distribution in isolation; the power of this study is derived from our ability to measure
multiple inhibitors bound to the same protein and order them by their ability to effect




















































































Figure A.1: Cdk2 inhibitors ordered by their ability to shift the balance between the
Aloop-in and Aloop-out states of Cdk2 with and without cyclinA. Not only does this
make for a pleasing visual, but it also drives home the point that the kinase is emphat-
ically not switch-like, but rather transitions in a graded fashion.
The conserved nature of the kinase fold facilitates interesting comparisons across
different kinases as well. For example, we performed a set of DEER experiments on
phosphorylated, monomeric Aurora A (pAurA), a kinase that regulates cell cycle cen-
trosome maturation and microtubule assembly, in the presence of several inhibitors
(Figure A.2)76. The results look superficially similar to those of Cdk2; pAurA samples
a continuum of conformational states intermediate between the DFG-in and DFG-out
extremes. It is important to notice that although AurA is also regulated by the binding
of other proteins (somewhat analogous to cyclins for the CDKs), unlike with Cdk2,
monomeric pAurA seems more conformationally flexible than monomeric Cdk2 and is



























Figure A.2: A sampling of Aurora A inhibitors ordered by their ability to shift the
balance between the DFG-in and DFG-out conformations of monomeric, phosphorylated
Aurora A. Adapted from [76].
